CHEBI ONTOLOGY - ANNOTATIONS |
|
The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
|
Term: | cytosine |
|
Accession: | CHEBI:16040
|
browse the term
|
Definition: | An aminopyrimidine that is pyrimidin-2-one having the amino group located at position 4. |
Synonyms: | exact_synonym: | 4-aminopyrimidin-2(1H)-one |
| related_synonym: | 4-amino-2(1H)-pyrimidinone; 4-amino-2-hydroxypyrimidine; C; Cyt; Cytosin; Formula=C4H5N3O; InChI=1S/C4H5N3O/c5-3-1-2-6-4(8)7-3/h1-2H,(H3,5,6,7,8); InChIKey=OPTASPLRGRRNAP-UHFFFAOYSA-N; SMILES=Nc1cc[nH]c(=O)n1; Zytosin |
| alt_id: | CHEBI:14066; CHEBI:23531; CHEBI:4072; CHEBI:41732 |
| xref: | CAS:71-30-7; Gmelin:82472; HMDB:HMDB0000630; KEGG:C00380; KNApSAcK:C00001498; MetaCyc:CYTOSINE; PDBeChem:CYT; PMID:14253484; PMID:22770225; PMID:7877593; Reaxys:2637; Wikipedia:Cytosine |
|
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
ISO |
Deoxycytidine inhibits the reaction [[9-deaza-9-(3-thienylmethyl)guanine co-treated with Deoxyguanosine] results in increased activity of CASP3 protein] |
CTD |
PMID:9297556 PMID:9403342 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Dck |
deoxycytidine kinase |
affects binding |
ISO |
Deoxycytidine binds to DCK protein |
CTD |
PMID:17530837 |
|
NCBI chr14:19,305,218...19,326,247
Ensembl chr14:19,305,218...19,326,247
|
|
G |
Slc28a1 |
solute carrier family 28 member 1 |
increases transport |
ISO |
SLC28A1 protein results in increased transport of Deoxycytidine |
CTD |
PMID:10772724 |
|
NCBI chr 1:135,079,375...135,122,791
Ensembl chr 1:135,081,385...135,122,464
|
|
|
G |
Cdipt |
CDP-diacylglycerol--inositol 3-phosphatidyltransferase |
multiple interactions |
ISO |
[delta-hexachlorocyclohexane results in decreased activity of CDIPT protein] which results in decreased abundance of Cytidine Monophosphate; [Inositol promotes the reaction [CDIPT protein results in increased metabolism of Cytidine Diphosphate Diglycerides]] which results in increased abundance of Cytidine Monophosphate |
CTD |
PMID:2579070 |
|
NCBI chr 1:181,583,098...181,587,409
Ensembl chr 1:181,583,141...181,587,408
|
|
|
G |
Mbd4 |
methyl-CpG binding domain 4 DNA glycosylase |
affects glycosylation |
ISO |
MBD4 protein affects the glycosylation of 3,N(4)-ethenocytosine |
CTD |
PMID:11056019 |
|
NCBI chr 4:148,893,049...148,904,833
Ensembl chr 4:148,894,280...148,904,982
|
|
G |
Tdg |
thymine-DNA glycosylase |
increases metabolic processing |
ISO |
TDG protein results in increased metabolism of 3,N(4)-ethenocytosine |
CTD |
PMID:10626224 |
|
NCBI chr 7:21,077,853...21,097,617
Ensembl chr 7:21,077,853...21,097,567
|
|
|
G |
Atm |
ATM serine/threonine kinase |
decreases methylation |
ISO |
5-hydroxymethylcytosine results in decreased methylation of ATM gene |
CTD |
PMID:30990028 |
|
NCBI chr 8:53,828,741...53,932,773
Ensembl chr 8:53,831,093...53,932,437
|
|
G |
Cmah |
cytidine monophospho-N-acetylneuraminic acid hydroxylase |
multiple interactions |
ISO |
[bisphenol A results in decreased methylation of CMAH intron] which results in decreased abundance of 5-hydroxymethylcytosine |
CTD |
PMID:30044229 |
|
NCBI chr17:40,557,161...40,642,350
Ensembl chr17:40,583,667...40,642,275
|
|
G |
Dnmt1 |
DNA methyltransferase 1 |
multiple interactions |
ISO |
DNMT1 protein promotes the reaction [bisphenol A results in decreased abundance of 5-hydroxymethylcytosine]; DNMT1 protein promotes the reaction [bisphenol S results in decreased abundance of 5-hydroxymethylcytosine] |
CTD |
PMID:32105160 |
|
NCBI chr 8:19,440,611...19,486,659
Ensembl chr 8:19,440,611...19,486,659
|
|
G |
Dnmt3a |
DNA methyltransferase 3 alpha |
multiple interactions |
ISO |
DNMT3A protein promotes the reaction [bisphenol A results in decreased abundance of 5-hydroxymethylcytosine]; DNMT3A protein promotes the reaction [bisphenol S results in decreased abundance of 5-hydroxymethylcytosine] |
CTD |
PMID:32105160 |
|
NCBI chr 6:26,791,517...26,902,161
Ensembl chr 6:26,822,609...26,896,687
|
|
G |
Esr1 |
estrogen receptor 1 |
decreases abundance multiple interactions |
ISO |
ESR1 protein results in decreased abundance of 5-hydroxymethylcytosine ESR1 protein promotes the reaction [bisphenol A results in decreased abundance of 5-hydroxymethylcytosine]; ESR1 protein promotes the reaction [bisphenol S results in decreased abundance of 5-hydroxymethylcytosine] |
CTD |
PMID:32105160 |
|
NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
|
|
G |
Ftl1 |
ferritin light chain 1 |
multiple interactions |
ISO |
[Chloranil results in increased abundance of 5-hydroxymethylcytosine] which results in increased expression of FTL mRNA |
CTD |
PMID:24214992 |
|
NCBI chr 1:95,936,387...95,938,234
Ensembl chr 1:95,936,387...95,939,725 Ensembl chr10:95,936,387...95,939,725 Ensembl chr 2:95,936,387...95,939,725
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
multiple interactions |
ISO |
[hydroquinone affects the methylation of GCLC promoter] which results in increased abundance of 5-hydroxymethylcytosine |
CTD |
PMID:23940045 |
|
NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544
|
|
G |
Gnas |
GNAS complex locus |
multiple interactions |
ISO |
[bisphenol A results in increased methylation of GNAS intron] which results in increased abundance of 5-hydroxymethylcytosine |
CTD |
PMID:30044229 |
|
NCBI chr 3:163,071,003...163,136,350
Ensembl chr 3:163,071,417...163,127,262 Ensembl chr 3:163,071,417...163,127,262
|
|
G |
Grb10 |
growth factor receptor bound protein 10 |
multiple interactions |
ISO |
[bisphenol A results in increased methylation of GRB10 intron] which results in increased abundance of 5-hydroxymethylcytosine |
CTD |
PMID:30044229 |
|
NCBI chr14:86,495,051...86,602,800
Ensembl chr14:86,495,054...86,602,806
|
|
G |
Idh2 |
isocitrate dehydrogenase (NADP(+)) 2 |
decreases abundance |
ISO |
IDH2 protein mutant form results in decreased abundance of 5-hydroxymethylcytosine |
CTD |
PMID:27469509 |
|
NCBI chr 1:134,038,644...134,057,969
Ensembl chr 1:134,029,772...134,058,025
|
|
G |
Kcnq1 |
potassium voltage-gated channel subfamily Q member 1 |
multiple interactions |
ISO |
[bisphenol A results in decreased methylation of KCNQ1 intron] which results in decreased abundance of 5-hydroxymethylcytosine |
CTD |
PMID:30044229 |
|
NCBI chr 1:198,291,711...198,624,683
Ensembl chr 1:198,291,766...198,624,669
|
|
G |
Klf14 |
KLF transcription factor 14 |
multiple interactions |
ISO |
[bisphenol A results in decreased methylation of KLF14 exon] which results in decreased abundance of 5-hydroxymethylcytosine |
CTD |
PMID:30044229 |
|
NCBI chr 4:59,554,011...59,556,933
Ensembl chr 4:59,554,011...59,556,933
|
|
G |
Pde10a |
phosphodiesterase 10A |
multiple interactions |
ISO |
[bisphenol A results in increased methylation of PDE10A intron] which results in increased abundance of 5-hydroxymethylcytosine |
CTD |
PMID:30044229 |
|
NCBI chr 1:51,765,743...52,218,086
Ensembl chr 1:51,770,132...52,216,563
|
|
G |
Pde4d |
phosphodiesterase 4D |
multiple interactions |
ISO |
[bisphenol A results in increased methylation of PDE4D exon] which results in increased abundance of 5-hydroxymethylcytosine |
CTD |
PMID:30044229 |
|
NCBI chr 2:40,014,933...41,529,190
Ensembl chr 2:40,019,933...41,525,884
|
|
G |
Plagl1 |
PLAG1 like zinc finger 1 |
multiple interactions |
ISO |
[bisphenol A results in increased methylation of PLAGL1 exon] which results in increased abundance of 5-hydroxymethylcytosine |
CTD |
PMID:30044229 |
|
NCBI chr 1:7,477,295...7,517,229
Ensembl chr 1:7,477,177...7,517,228
|
|
G |
Ppp1r9a |
protein phosphatase 1, regulatory subunit 9A |
multiple interactions |
ISO |
[bisphenol A results in decreased methylation of PPP1R9A intron] which results in decreased abundance of 5-hydroxymethylcytosine |
CTD |
PMID:30044229 |
|
NCBI chr 4:32,970,501...33,292,360
Ensembl chr 4:33,024,450...33,286,907
|
|
G |
Sfn |
stratifin |
multiple interactions |
ISO |
[hydroquinone affects the methylation of SFN promoter] which results in increased abundance of 5-hydroxymethylcytosine |
CTD |
PMID:23940045 |
|
NCBI chr 5:145,826,722...145,827,994
Ensembl chr 5:145,826,201...145,831,314
|
|
G |
Tet1 |
tet methylcytosine dioxygenase 1 |
multiple interactions |
ISO |
TET1 protein affects the reaction [2,3,5,6-tetrachlorohydroquinone results in increased chemical synthesis of 5-hydroxymethylcytosine]; TET1 protein affects the reaction [Chloranil results in increased chemical synthesis of 5-hydroxymethylcytosine] |
CTD |
PMID:24214992 |
|
NCBI chr20:25,761,042...25,840,926
Ensembl chr20:25,768,120...25,833,052
|
|
G |
Tet2 |
tet methylcytosine dioxygenase 2 |
multiple interactions increases abundance |
ISO |
TET2 protein affects the reaction [2,3,5,6-tetrachlorohydroquinone results in increased chemical synthesis of 5-hydroxymethylcytosine]; TET2 protein affects the reaction [Chloranil results in increased chemical synthesis of 5-hydroxymethylcytosine] TET2 protein results in increased abundance of 5-hydroxymethylcytosine bisphenol A promotes the reaction [TET2 protein results in increased abundance of 5-hydroxymethylcytosine]; bisphenol S promotes the reaction [TET2 protein results in increased abundance of 5-hydroxymethylcytosine]; TET2 protein inhibits the reaction [bisphenol A results in decreased abundance of 5-hydroxymethylcytosine]; TET2 protein inhibits the reaction [bisphenol S results in decreased abundance of 5-hydroxymethylcytosine] |
CTD |
PMID:24214992 PMID:32105160 |
|
NCBI chr 2:221,988,645...222,072,813
Ensembl chr 2:221,988,645...222,072,534
|
|
G |
Ubc |
ubiquitin C |
multiple interactions |
ISO |
[Chloranil results in increased abundance of 5-hydroxymethylcytosine] which results in increased expression of UBC mRNA |
CTD |
PMID:24214992 |
|
NCBI chr12:31,239,149...31,243,924
Ensembl chr12:31,239,152...31,243,925
|
|
|
G |
Cda |
cytidine deaminase |
increases metabolic processing |
ISO |
CDA protein results in increased metabolism of 5-fluorocytidine |
CTD |
PMID:21804305 |
|
NCBI chr 5:150,556,615...150,583,231
Ensembl chr 5:150,556,615...150,583,231
|
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
multiple interactions |
ISO |
[hydroquinone affects the methylation of GCLC promoter] which results in decreased abundance of 5-Methylcytosine |
CTD |
PMID:23940045 |
|
NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544
|
|
G |
Sfn |
stratifin |
multiple interactions |
ISO |
[hydroquinone affects the methylation of SFN promoter] which results in decreased abundance of 5-Methylcytosine |
CTD |
PMID:23940045 |
|
NCBI chr 5:145,826,722...145,827,994
Ensembl chr 5:145,826,201...145,831,314
|
|
G |
Tet1 |
tet methylcytosine dioxygenase 1 |
multiple interactions |
ISO |
TET1 protein affects the reaction [2,3,5,6-tetrachlorohydroquinone results in increased oxidation of 5-Methylcytosine]; TET1 protein affects the reaction [Chloranil results in increased oxidation of 5-Methylcytosine] |
CTD |
PMID:24214992 |
|
NCBI chr20:25,761,042...25,840,926
Ensembl chr20:25,768,120...25,833,052
|
|
G |
Tet2 |
tet methylcytosine dioxygenase 2 |
multiple interactions |
ISO |
TET2 protein affects the reaction [2,3,5,6-tetrachlorohydroquinone results in increased oxidation of 5-Methylcytosine]; TET2 protein affects the reaction [Chloranil results in increased oxidation of 5-Methylcytosine] |
CTD |
PMID:24214992 |
|
NCBI chr 2:221,988,645...222,072,813
Ensembl chr 2:221,988,645...222,072,534
|
|
G |
Wrap53 |
WD repeat containing, antisense to TP53 |
multiple interactions |
ISO |
[Pesticides results in increased methylation of WRAP53 gene] which results in increased abundance of 5-Methylcytosine |
CTD |
PMID:31243981 |
|
NCBI chr10:54,282,092...54,299,908
Ensembl chr10:54,282,105...54,298,929
|
|
|
G |
Abcb7 |
ATP binding cassette subfamily B member 7 |
decreases response to substance |
ISO |
ABCB7 protein results in decreased susceptibility to Capecitabine |
CTD |
PMID:16734730 |
|
NCBI chr X:69,295,598...69,436,775
Ensembl chr X:69,295,552...69,436,858
|
|
G |
Acaa1a |
acetyl-CoA acyltransferase 1A |
increases response to substance |
ISO |
ACAA1 protein results in increased susceptibility to Capecitabine |
CTD |
PMID:16734730 |
|
NCBI chr 8:119,079,401...119,088,626
Ensembl chr 8:119,079,775...119,088,624
|
|
G |
Agpat2 |
1-acylglycerol-3-phosphate O-acyltransferase 2 |
increases response to substance |
ISO |
AGPAT2 protein results in increased susceptibility to Capecitabine |
CTD |
PMID:16734730 |
|
NCBI chr 3:9,416,837...9,428,567
Ensembl chr 3:9,416,843...9,428,371
|
|
G |
Agr2 |
anterior gradient 2, protein disulphide isomerase family member |
increases response to substance |
ISO |
AGR2 protein results in increased susceptibility to Capecitabine |
CTD |
PMID:16734730 |
|
NCBI chr 6:52,708,602...52,729,378
Ensembl chr 6:52,708,602...52,729,371
|
|
G |
Akr1b1 |
aldo-keto reductase family 1 member B1 |
decreases response to substance |
ISO |
AKR1B1 protein results in decreased susceptibility to Capecitabine |
CTD |
PMID:16734730 |
|
NCBI chr 4:62,932,033...62,946,126
Ensembl chr 4:62,932,031...62,946,157
|
|
G |
Akr1c3 |
aldo-keto reductase family 1, member C3 |
increases response to substance |
ISO |
AKR1C3 protein results in increased susceptibility to Capecitabine |
CTD |
PMID:16734730 |
|
NCBI chr17:66,110,970...66,127,867
Ensembl chr17:66,110,963...66,127,873
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions |
ISO |
capecitabine decreases expression and phosphorylation of AKT1 protein in colon |
RGD |
PMID:30789971 |
RGD:151893289 |
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Aqp8 |
aquaporin 8 |
increases expression |
ISO |
Capecitabine results in increased expression of AQP8 mRNA |
CTD |
PMID:36183961 |
|
NCBI chr 1:177,993,313...177,999,158
Ensembl chr 1:177,993,305...177,999,158
|
|
G |
Arl4d |
ARF like GTPase 4D |
decreases response to substance |
ISO |
ARL4D protein results in decreased susceptibility to Capecitabine |
CTD |
PMID:16734730 |
|
NCBI chr10:86,592,054...86,602,843
Ensembl chr10:86,595,661...86,602,836
|
|
G |
Atp12a |
ATPase H+/K+ transporting non-gastric alpha2 subunit |
increases expression |
ISO |
Capecitabine results in increased expression of ATP12A mRNA |
CTD |
PMID:36183961 |
|
NCBI chr15:30,443,571...30,468,229
Ensembl chr15:30,443,571...30,468,229
|
|
G |
Axl |
Axl receptor tyrosine kinase |
decreases response to substance |
ISO |
AXL protein results in decreased susceptibility to Capecitabine |
CTD |
PMID:16734730 |
|
NCBI chr 1:81,265,088...81,296,278
Ensembl chr 1:81,265,088...81,296,265
|
|
G |
C3 |
complement C3 |
decreases expression |
ISO |
Capecitabine results in decreased expression of C3 mRNA |
CTD |
PMID:36183961 |
|
NCBI chr 9:2,087,437...2,114,366
Ensembl chr 9:2,087,437...2,114,429
|
|
G |
Canx |
calnexin |
multiple interactions |
ISO |
CANX results in decreased susceptibility to [Fluorouracil co-treated with Capecitabine] |
CTD |
PMID:18678097 |
|
NCBI chr10:34,623,865...34,656,866
Ensembl chr10:34,625,191...34,656,821
|
|
G |
Cat |
catalase |
decreases activity |
EXP |
Capecitabine results in decreased activity of CAT protein |
CTD |
PMID:29117755 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccl19 |
C-C motif chemokine ligand 19 |
decreases expression |
ISO |
Capecitabine results in decreased expression of CCL19 mRNA |
CTD |
PMID:36183961 |
|
NCBI chr 5:56,963,364...56,965,308
Ensembl chr 5:56,963,364...56,965,308
|
|
G |
Ccl21 |
C-C motif chemokine ligand 21 |
decreases expression |
ISO |
Capecitabine results in decreased expression of CCL21 mRNA |
CTD |
PMID:36183961 |
|
NCBI chr 5:56,980,557...56,981,661
Ensembl chr 5:56,980,558...56,981,686
|
|
G |
Ccn1 |
cellular communication network factor 1 |
decreases response to substance decreases expression |
ISO |
CCN1 protein results in decreased susceptibility to Capecitabine Capecitabine results in decreased expression of CCN1 mRNA |
CTD |
PMID:16734730 PMID:36183961 |
|
NCBI chr 2:234,562,410...234,565,370
Ensembl chr 2:234,562,408...234,565,484
|
|
G |
Cdkn2a |
cyclin-dependent kinase inhibitor 2A |
decreases expression |
ISO |
Capecitabine results in decreased expression of CDKN2A protein |
CTD |
PMID:17904787 |
|
NCBI chr 5:103,984,949...103,992,143
Ensembl chr 5:103,984,949...104,003,149
|
|
G |
Ces1d |
carboxylesterase 1D |
multiple interactions |
ISO |
CES1 protein results in increased hydrolysis of and results in increased activity of Capecitabine |
CTD |
PMID:15687373 |
|
NCBI chr19:13,873,490...13,912,035
Ensembl chr19:13,796,623...13,912,035
|
|
G |
Ces2h |
carboxylesterase 2H |
multiple interactions increases response to substance |
ISO |
CES2 protein results in increased hydrolysis of and results in increased activity of Capecitabine CES2 gene polymorphism results in increased susceptibility to Capecitabine |
CTD |
PMID:15687373 PMID:18473752 |
|
NCBI chr19:32,974,242...32,988,842
Ensembl chr19:32,974,242...32,988,830
|
|
G |
Cib1 |
calcium and integrin binding 1 |
increases response to substance |
ISO |
CIB1 protein results in increased susceptibility to Capecitabine |
CTD |
PMID:16734730 |
|
NCBI chr 1:134,178,331...134,183,895
Ensembl chr 1:134,178,331...134,213,423
|
|
G |
Cldn3 |
claudin 3 |
increases response to substance |
ISO |
CLDN3 protein results in increased susceptibility to Capecitabine |
CTD |
PMID:16734730 |
|
NCBI chr12:21,708,538...21,710,010
Ensembl chr12:21,708,398...21,711,001
|
|
G |
Cxcl12 |
C-X-C motif chemokine ligand 12 |
decreases expression |
ISO |
Capecitabine decreases expression of CXCL12 protein in liver and colon |
RGD |
PMID:30789971 |
RGD:151893289 |
NCBI chr 4:150,388,326...150,401,173
Ensembl chr 4:150,388,325...150,401,168
|
|
G |
Cxcl3 |
C-X-C motif chemokine ligand 3 |
increases expression |
ISO |
Capecitabine results in increased expression of CXCL1 |
CTD |
PMID:35147423 |
|
NCBI chr14:17,287,727...17,289,451
Ensembl chr14:17,270,146...17,289,511
|
|
G |
Cxcr4 |
C-X-C motif chemokine receptor 4 |
decreases expression |
ISO |
Capecitabine decreases expression of CXCR4 protein in liver and colon |
RGD |
PMID:30789971 |
RGD:151893289 |
NCBI chr13:40,077,976...40,081,883
Ensembl chr13:40,077,976...40,081,883
|
|
G |
Dpyd |
dihydropyrimidine dehydrogenase |
increases expression decreases response to substance affects response to substance |
ISO |
Capecitabine results in increased expression of DPYD mRNA DPYD protein results in decreased susceptibility to Capecitabine DPYD protein affects the susceptibility to Capecitabine |
CTD |
PMID:16734730 PMID:17611699 PMID:18846242 |
|
NCBI chr 2:206,609,043...207,474,982
Ensembl chr 2:206,609,122...207,474,982
|
|
G |
Dse |
dermatan sulfate epimerase |
decreases response to substance |
ISO |
DSE protein results in decreased susceptibility to Capecitabine |
CTD |
PMID:16734730 |
|
NCBI chr20:26,118,194...26,196,889
Ensembl chr20:26,118,196...26,196,992
|
|
G |
Eps8 |
EGFR pathway substrate 8, signaling adaptor |
increases response to substance |
ISO |
EPS8 protein results in increased susceptibility to Capecitabine |
CTD |
PMID:16734730 |
|
NCBI chr 4:170,388,378...170,486,873
Ensembl chr 4:170,388,378...170,486,873
|
|
G |
Erbb3 |
erb-b2 receptor tyrosine kinase 3 |
increases response to substance |
ISO |
ERBB3 protein results in increased susceptibility to Capecitabine |
CTD |
PMID:16734730 |
|
NCBI chr 7:994,549...1,015,876
Ensembl chr 7:996,225...1,015,525
|
|
G |
Fcrla |
Fc receptor-like A |
decreases expression |
ISO |
Capecitabine results in decreased expression of FCRLA mRNA |
CTD |
PMID:36183961 |
|
NCBI chr13:83,160,453...83,170,170
Ensembl chr13:83,160,398...83,170,762
|
|
G |
Fhl1 |
four and a half LIM domains 1 |
decreases response to substance |
ISO |
FHL1 protein results in decreased susceptibility to Capecitabine |
CTD |
PMID:16734730 |
|
NCBI chr X:134,555,399...134,614,930
Ensembl chr X:134,555,479...134,614,928
|
|
G |
Flii |
FLII, actin remodeling protein |
decreases response to substance |
ISO |
FLII protein results in decreased susceptibility to Capecitabine |
CTD |
PMID:16734730 |
|
NCBI chr10:45,394,032...45,408,051
Ensembl chr10:45,394,032...45,407,970
|
|
G |
Fuca1 |
alpha-L-fucosidase 1 |
increases response to substance |
ISO |
FUCA1 protein results in increased susceptibility to Capecitabine |
CTD |
PMID:16734730 |
|
NCBI chr 5:148,152,718...148,169,972
Ensembl chr 5:148,152,700...148,169,972
|
|
G |
Gatd3a |
glutamine amidotransferase class 1 domain containing 3A |
increases expression |
ISO |
Capecitabine results in increased expression of GATD3A mRNA |
CTD |
PMID:36183961 |
|
NCBI chr20:10,514,793...10,522,894
Ensembl chr20:10,514,744...10,522,885
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
decreases activity |
EXP |
Capecitabine results in decreased activity of GPX1 protein |
CTD |
PMID:29117755 |
|
NCBI chr 8:109,026,905...109,028,031
Ensembl chr 8:109,026,905...109,028,024
|
|
G |
Hba-a2 |
hemoglobin alpha, adult chain 2 |
decreases expression |
ISO |
Capecitabine results in decreased expression of HBA1 mRNA |
CTD |
PMID:36183961 |
|
NCBI chr10:15,323,830...15,324,677
Ensembl chr10:15,307,815...15,338,392 Ensembl chr10:15,307,815...15,338,392
|
|
G |
Hba-a3 |
hemoglobin alpha, adult chain 3 |
decreases expression |
ISO |
Capecitabine results in decreased expression of HBA2 mRNA |
CTD |
PMID:36183961 |
|
NCBI chr10:15,311,637...15,312,481
Ensembl chr10:15,311,634...15,312,481
|
|
G |
Hbb |
hemoglobin subunit beta |
decreases expression |
ISO |
Capecitabine results in decreased expression of HBB mRNA |
CTD |
PMID:36183961 |
|
NCBI chr 1:158,250,421...158,251,832
Ensembl chr 1:158,120,200...158,252,012
|
|
G |
Hdgfl3 |
HDGF like 3 |
decreases response to substance |
ISO |
HDGFL3 protein results in decreased susceptibility to Capecitabine |
CTD |
PMID:16734730 |
|
NCBI chr 1:135,822,600...135,876,719
Ensembl chr 1:135,827,549...135,876,719
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
decreases response to substance ameliorates |
ISO |
HIF1A protein results in decreased susceptibility to Capecitabine capecitabine decreases expression of HIF1A protein in colon |
CTD RGD |
PMID:16734730 PMID:30789971 |
RGD:151893289 |
NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261
|
|
G |
Hras |
HRas proto-oncogene, GTPase |
decreases response to substance |
ISO |
HRAS protein results in decreased susceptibility to Capecitabine |
CTD |
PMID:16734730 |
|
NCBI chr 1:196,290,127...196,299,823
Ensembl chr 1:196,296,263...196,300,615
|
|
G |
Il17rb |
interleukin 17 receptor B |
increases response to substance |
ISO |
IL17RB protein results in increased susceptibility to Capecitabine |
CTD |
PMID:16734730 |
|
NCBI chr16:5,180,431...5,194,125
Ensembl chr16:5,180,432...5,194,125
|
|
G |
Il1r2 |
interleukin 1 receptor type 2 |
increases response to substance |
ISO |
IL1R2 protein results in increased susceptibility to Capecitabine |
CTD |
PMID:16734730 |
|
NCBI chr 9:42,384,280...42,424,726
Ensembl chr 9:42,384,433...42,424,725
|
|
G |
Il6 |
interleukin 6 |
increases expression multiple interactions |
ISO |
Capecitabine metabolite results in increased expression of IL6 mRNA; Capecitabine results in increased expression of IL6 alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide inhibits the reaction [Capecitabine metabolite results in increased expression of IL6 mRNA] |
CTD |
PMID:35147423 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Junb |
JunB proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
ISO |
JUNB results in decreased susceptibility to [Fluorouracil co-treated with Capecitabine] |
CTD |
PMID:18678097 |
|
NCBI chr19:23,176,265...23,178,049
Ensembl chr19:23,176,294...23,178,035
|
|
G |
Lgals4 |
galectin 4 |
increases response to substance |
ISO |
LGALS4 protein results in increased susceptibility to Capecitabine |
CTD |
PMID:16734730 |
|
NCBI chr 1:84,124,766...84,132,481
Ensembl chr 1:84,124,764...84,132,481
|
|
G |
Lrrc15 |
leucine rich repeat containing 15 |
decreases expression |
ISO |
Capecitabine results in decreased expression of LRRC15 mRNA |
CTD |
PMID:36183961 |
|
NCBI chr11:70,469,817...70,484,268
Ensembl chr11:70,469,804...70,484,267
|
|
G |
Mdm4 |
MDM4 regulator of p53 |
multiple interactions |
ISO |
MDM4 results in decreased susceptibility to [Fluorouracil co-treated with Capecitabine] |
CTD |
PMID:18678097 |
|
NCBI chr13:44,432,596...44,516,165
Ensembl chr13:44,406,213...44,474,226
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
multiple interactions decreases expression |
ISO |
MMP2 results in decreased susceptibility to [Fluorouracil co-treated with Capecitabine] capecitabine decreases expression of MMP2 protein in colon |
CTD RGD |
PMID:18678097 PMID:30789971 |
RGD:151893289 |
NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870
|
|
G |
Mre11 |
MRE11 homolog, double strand break repair nuclease |
decreases response to substance |
ISO |
MRE11 protein results in decreased susceptibility to Capecitabine |
CTD |
PMID:16734730 |
|
NCBI chr 8:11,618,876...11,680,451
Ensembl chr 8:11,632,354...11,678,279
|
|
G |
Ms4a1 |
membrane spanning 4-domains A1 |
decreases expression |
ISO |
Capecitabine results in decreased expression of MS4A1 mRNA |
CTD |
PMID:36183961 |
|
NCBI chr 1:207,906,370...207,927,028
Ensembl chr 1:207,906,374...207,918,512
|
|
G |
Myb |
MYB proto-oncogene, transcription factor |
increases response to substance |
ISO |
MYB protein results in increased susceptibility to Capecitabine |
CTD |
PMID:16734730 |
|
NCBI chr 1:15,939,771...15,973,367
Ensembl chr 1:15,939,761...15,973,057
|
|
G |
Myrf |
myelin regulatory factor |
increases response to substance |
ISO |
MYRF protein results in increased susceptibility to Capecitabine |
CTD |
PMID:16734730 |
|
NCBI chr 1:206,854,175...206,886,276
Ensembl chr 1:206,854,175...206,886,157
|
|
G |
Nr4a1 |
nuclear receptor subfamily 4, group A, member 1 |
decreases expression |
ISO |
Capecitabine results in decreased expression of NR4A1 mRNA |
CTD |
PMID:36183961 |
|
NCBI chr 7:132,368,399...132,389,300
Ensembl chr 7:132,374,840...132,389,297
|
|
G |
Nr4a2 |
nuclear receptor subfamily 4, group A, member 2 |
decreases expression |
ISO |
Capecitabine results in decreased expression of NR4A2 mRNA |
CTD |
PMID:36183961 |
|
NCBI chr 3:41,689,847...41,707,036
Ensembl chr 3:41,689,851...41,697,877
|
|
G |
Pax5 |
paired box 5 |
decreases expression |
ISO |
Capecitabine results in decreased expression of PAX5 mRNA |
CTD |
PMID:36183961 |
|
NCBI chr 5:58,763,334...58,945,719
Ensembl chr 5:58,765,036...58,944,326
|
|
G |
Pik3cb |
phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit beta |
multiple interactions |
ISO |
capecitabine decreases expression and phosphorylation of PIK3CB protein in colon |
RGD |
PMID:30789971 |
RGD:151893289 |
NCBI chr 8:99,594,600...99,699,772
Ensembl chr 8:99,594,644...99,699,663
|
|
G |
Pkd2 |
polycystin 2, transient receptor potential cation channel |
decreases response to substance |
ISO |
PKD2 protein results in decreased susceptibility to Capecitabine |
CTD |
PMID:16734730 |
|
NCBI chr14:5,237,135...5,280,455
Ensembl chr14:5,237,135...5,280,825
|
|
G |
Pkp2 |
plakophilin 2 |
increases response to substance |
ISO |
PKP2 protein results in increased susceptibility to Capecitabine |
CTD |
PMID:16734730 |
|
NCBI chr11:84,661,783...84,727,730
Ensembl chr11:84,661,783...84,727,730
|
|
G |
Plce1 |
phospholipase C, epsilon 1 |
increases response to substance |
ISO |
PLCE1 protein results in increased susceptibility to Capecitabine |
CTD |
PMID:16734730 |
|
NCBI chr 1:236,243,445...236,552,571
Ensembl chr 1:236,244,683...236,551,438
|
|
G |
Ppa1 |
inorganic pyrophosphatase 1 |
increases response to substance |
ISO |
PPA1 protein results in increased susceptibility to Capecitabine |
CTD |
PMID:16734730 |
|
NCBI chr20:29,590,733...29,617,711
Ensembl chr20:29,590,707...29,619,215
|
|
G |
Prkacb |
protein kinase cAMP-activated catalytic subunit beta |
decreases response to substance |
ISO |
PRKACB protein results in decreased susceptibility to Capecitabine |
CTD |
PMID:16734730 |
|
NCBI chr 2:235,636,878...235,726,928
Ensembl chr 2:235,636,885...235,726,198
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
decreases expression |
ISO |
Capecitabine results in decreased expression of PTGS2 protein Capecitabine metabolite results in decreased expression of PTGS2 |
CTD |
PMID:17904787 PMID:35147423 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Ptpn13 |
protein tyrosine phosphatase, non-receptor type 13 |
decreases response to substance |
ISO |
PTPN13 protein results in decreased susceptibility to Capecitabine |
CTD |
PMID:16734730 |
|
NCBI chr14:6,108,202...6,282,619
Ensembl chr14:6,108,211...6,282,563
|
|
G |
Pygb |
glycogen phosphorylase B |
increases response to substance |
ISO |
PYGB protein results in increased susceptibility to Capecitabine |
CTD |
PMID:16734730 |
|
NCBI chr 3:139,611,724...139,658,521
Ensembl chr 3:139,611,749...139,663,553
|
|
G |
Rab40b |
Rab40b, member RAS oncogene family |
increases response to substance |
ISO |
RAB40B protein results in increased susceptibility to Capecitabine |
CTD |
PMID:16734730 |
|
NCBI chr10:106,631,514...106,659,090
Ensembl chr10:106,631,514...106,659,090
|
|
G |
Rb1 |
RB transcriptional corepressor 1 |
multiple interactions |
ISO |
RB1 results in decreased susceptibility to [Fluorouracil co-treated with Capecitabine] |
CTD |
PMID:18678097 |
|
NCBI chr15:48,371,295...48,502,473
Ensembl chr15:48,371,296...48,502,302
|
|
G |
Rbbp4 |
RB binding protein 4, chromatin remodeling factor |
multiple interactions |
ISO |
RBBP4 results in decreased susceptibility to [Fluorouracil co-treated with Capecitabine] |
CTD |
PMID:18678097 |
|
NCBI chr 5:141,655,863...141,675,157
Ensembl chr 5:141,638,421...141,675,284 Ensembl chr 2:141,638,421...141,675,284
|
|
G |
Rpa1 |
replication protein A1 |
decreases response to substance |
ISO |
RPA1 protein results in decreased susceptibility to Capecitabine |
CTD |
PMID:16734730 |
|
NCBI chr10:60,148,869...60,199,970
Ensembl chr10:60,148,793...60,199,949
|
|
G |
Rras2 |
RAS related 2 |
decreases response to substance |
ISO |
RRAS2 protein results in decreased susceptibility to Capecitabine |
CTD |
PMID:16734730 |
|
NCBI chr 1:168,233,693...168,303,111
Ensembl chr 1:168,233,693...168,303,111
|
|
G |
RT1-Ba |
RT1 class II, locus Ba |
decreases expression |
ISO |
Capecitabine results in decreased expression of HLA-DQA1 mRNA |
CTD |
PMID:36183961 |
|
NCBI chr20:4,575,134...4,579,727
Ensembl chr20:4,575,134...4,579,744
|
|
G |
Sik1 |
salt-inducible kinase 1 |
decreases expression |
ISO |
Capecitabine results in decreased expression of SIK1 mRNA |
CTD |
PMID:36183961 |
|
NCBI chr20:9,949,407...9,959,036
Ensembl chr20:9,947,396...9,958,991
|
|
G |
Slc26a3 |
solute carrier family 26 member 3 |
increases expression |
ISO |
Capecitabine results in increased expression of SLC26A3 mRNA |
CTD |
PMID:36183961 |
|
NCBI chr 6:48,023,892...48,064,829
Ensembl chr 6:48,023,892...48,064,772
|
|
G |
Slco2b1 |
solute carrier organic anion transporter family, member 2b1 |
multiple interactions |
ISO |
Capecitabine inhibits the reaction [SLCO2B1 protein results in increased uptake of Cascade Blue] |
CTD |
PMID:30863990 |
|
NCBI chr 1:153,959,288...154,007,294
Ensembl chr 1:153,959,293...154,007,353
|
|
G |
Sod1 |
superoxide dismutase 1 |
decreases activity |
EXP |
Capecitabine results in decreased activity of SOD1 protein |
CTD |
PMID:29117755 |
|
NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249
|
|
G |
Stip1 |
stress-induced phosphoprotein 1 |
decreases response to substance |
ISO |
STIP1 protein results in decreased susceptibility to Capecitabine |
CTD |
PMID:16734730 |
|
NCBI chr 1:204,209,433...204,228,452
Ensembl chr 1:204,178,932...204,228,476
|
|
G |
Tcf7l2 |
transcription factor 7 like 2 |
multiple interactions |
ISO |
TCF7L2 results in decreased susceptibility to [Fluorouracil co-treated with Capecitabine] |
CTD |
PMID:18678097 |
|
NCBI chr 1:254,785,956...254,978,967
Ensembl chr 1:254,786,091...254,978,967
|
|
G |
Tead1 |
TEA domain transcription factor 1 |
decreases response to substance |
ISO |
TEAD1 protein results in decreased susceptibility to Capecitabine |
CTD |
PMID:16734730 |
|
NCBI chr 1:166,791,900...167,010,591
Ensembl chr 1:166,792,628...167,003,369
|
|
G |
Tff1 |
trefoil factor 1 |
increases response to substance |
ISO |
TFF1 protein results in increased susceptibility to Capecitabine |
CTD |
PMID:16734730 |
|
NCBI chr20:9,235,736...9,239,597
Ensembl chr20:9,235,736...9,239,597
|
|
G |
Trim15 |
tripartite motif containing 15 |
increases response to substance |
ISO |
TRIM15 protein results in increased susceptibility to Capecitabine |
CTD |
PMID:16734730 |
|
NCBI chr20:1,700,905...1,710,249
Ensembl chr20:1,700,905...1,710,249
|
|
G |
Trim31 |
tripartite motif-containing 31 |
increases expression |
ISO |
Capecitabine results in increased expression of TRIM31 mRNA |
CTD |
PMID:36183961 |
|
NCBI chr20:1,653,165...1,666,494
Ensembl chr20:1,653,165...1,666,494
|
|
G |
Tyms |
thymidylate synthetase |
affects expression decreases response to substance multiple interactions |
ISO |
Capecitabine affects the expression of TYMS mRNA TYMS protein results in decreased susceptibility to Capecitabine [TYMS enhancer polymorphism co-treated with VEGFA gene SNP] affects the susceptibility to [Capecitabine co-treated with oxaliplatin] |
CTD |
PMID:16438929 PMID:16734730 PMID:21048041 |
|
NCBI chr 9:113,313,454...113,329,551
Ensembl chr 9:113,313,452...113,329,536
|
|
G |
Upk3a |
uroplakin 3A |
increases expression |
ISO |
Capecitabine results in increased expression of UPK3A mRNA |
CTD |
PMID:36183961 |
|
NCBI chr 7:116,128,981...116,139,950
Ensembl chr 7:116,134,874...116,139,948
|
|
G |
Vegfa |
vascular endothelial growth factor A |
multiple interactions decreases expression |
ISO |
[TYMS enhancer polymorphism co-treated with VEGFA gene SNP] affects the susceptibility to [Capecitabine co-treated with oxaliplatin] capecitabine decreases expression of VEGFA protein in blood serum and colon |
CTD RGD |
PMID:21048041 PMID:30789971 |
RGD:151893289 |
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
G |
Zfp706 |
zinc finger protein 706 |
increases response to substance |
ISO |
ZNF706 protein results in increased susceptibility to Capecitabine |
CTD |
PMID:16734730 |
|
NCBI chr 7:68,167,496...68,174,121
Ensembl chr 7:68,166,323...68,174,148
|
|
|
G |
Casp3 |
caspase 3 |
decreases expression |
ISO |
Cytidine Diphosphate Choline results in decreased expression of CASP3 protein |
CTD |
PMID:12443983 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
decreases expression |
EXP |
Cytidine Diphosphate Choline results in decreased expression of ICAM1 mRNA |
CTD |
PMID:16193989 |
|
NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438
|
|
G |
Nceh1 |
neutral cholesterol ester hydrolase 1 |
multiple interactions |
ISO |
NCEH1 protein inhibits the reaction [[Chlorpyrifos metabolite co-treated with Cytidine Diphosphate Choline] results in increased abundance of Platelet Activating Factor] |
CTD |
PMID:18164358 |
|
NCBI chr 2:110,074,985...110,135,592
Ensembl chr 2:110,074,957...110,135,588
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
decreases expression |
ISO |
Cytidine Diphosphate Choline results in decreased expression of PARP1 protein modified form |
CTD |
PMID:12443983 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Sirt1 |
sirtuin 1 |
increases expression multiple interactions |
EXP |
Cytidine Diphosphate Choline results in increased expression of SIRT1 protein Cytidine Diphosphate Choline results in increased expression of and results in increased activity of SIRT1 protein |
CTD |
PMID:23600725 |
|
NCBI chr20:25,307,225...25,329,273
Ensembl chr20:25,306,917...25,329,260
|
|
|
G |
Cmas |
cytidine monophosphate N-acetylneuraminic acid synthetase |
affects abundance |
ISO |
CMAS protein affects the abundance of Cytidine Monophosphate N-Acetylneuraminic Acid |
CTD |
PMID:27380425 |
|
NCBI chr 4:175,718,808...175,737,128
Ensembl chr 4:175,718,808...175,737,125
|
|
|
G |
Ahr |
aryl hydrocarbon receptor |
multiple interactions |
EXP |
Cytidine Triphosphate affects the folding of [Tetrachlorodibenzodioxin binds to AHR protein] |
CTD |
PMID:1848756 |
|
NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568
|
|
G |
App |
amyloid beta precursor protein |
increases secretion |
ISO |
Cytidine Triphosphate results in increased secretion of APP protein modified form |
CTD |
PMID:22906069 |
|
NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561
|
|
G |
P2rx1 |
purinergic receptor P2X 1 |
affects binding |
EXP |
CTP binds to P2rx1 protein |
RGD |
PMID:12237343 |
RGD:727431 |
NCBI chr10:57,618,586...57,633,648
Ensembl chr10:57,618,586...57,633,623
|
|
G |
P2rx5 |
purinergic receptor P2X 5 |
affects transport |
EXP |
CTP affects transport ion flux of P2rx5 receptor |
RGD |
PMID:12237343 |
RGD:727431 |
NCBI chr10:57,777,737...57,789,426
Ensembl chr10:57,777,819...57,789,423
|
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
affects response to substance increases expression |
ISO |
ABCB1 protein affects the susceptibility to Cytarabine Cytarabine results in increased expression of ABCB1 |
CTD |
PMID:11573427 PMID:17852453 |
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Abcc1 |
ATP binding cassette subfamily C member 1 |
affects response to substance |
ISO |
ABCC1 protein affects the susceptibility to Cytarabine |
CTD |
PMID:17852453 |
|
NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114
|
|
G |
Acap1 |
ArfGAP with coiled-coil, ankyrin repeat and PH domains 1 |
increases expression |
ISO |
Cytarabine results in increased expression of ACAP1 mRNA |
CTD |
PMID:19194470 |
|
NCBI chr10:54,605,323...54,619,472
Ensembl chr10:54,605,323...54,619,472
|
|
G |
Ache |
acetylcholinesterase |
multiple interactions increases activity |
EXP |
betanin inhibits the reaction [Cytarabine results in increased activity of ACHE protein]; thymoquinone inhibits the reaction [Cytarabine results in increased activity of ACHE protein]; Vitamin D inhibits the reaction [Cytarabine results in increased activity of ACHE protein] |
CTD |
PMID:36419121 |
|
NCBI chr12:19,406,133...19,413,713
Ensembl chr12:19,407,360...19,413,651
|
|
G |
Acta1 |
actin, alpha 1, skeletal muscle |
increases expression |
ISO |
Cytarabine results in increased expression of ACTA1 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr19:51,883,709...51,886,735
Ensembl chr19:51,883,715...51,886,742
|
|
G |
Actc1 |
actin, alpha, cardiac muscle 1 |
decreases expression |
ISO |
Cytarabine results in decreased expression of ACTC1 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 3:100,811,987...100,817,523
Ensembl chr 3:100,811,987...100,817,523
|
|
G |
Adam19 |
ADAM metallopeptidase domain 19 |
decreases expression |
ISO |
Cytarabine results in decreased expression of ADAM19 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr10:30,491,362...30,583,115
Ensembl chr10:30,491,405...30,583,105
|
|
G |
Adamts1 |
ADAM metallopeptidase with thrombospondin type 1 motif, 1 |
decreases expression |
ISO |
Cytarabine results in decreased expression of ADAMTS1 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr11:24,932,227...24,941,068
Ensembl chr11:24,931,761...24,941,103
|
|
G |
Adamts9 |
ADAM metallopeptidase with thrombospondin type 1 motif, 9 |
decreases expression |
ISO |
Cytarabine results in decreased expression of ADAMTS9 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 4:125,290,633...125,462,988
Ensembl chr 4:125,291,490...125,462,929
|
|
G |
Adgrb3 |
adhesion G protein-coupled receptor B3 |
increases expression |
ISO |
Cytarabine results in increased expression of ADGRB3 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 9:27,421,168...28,148,979
Ensembl chr 9:27,421,168...28,148,855
|
|
G |
Adipoq |
adiponectin, C1Q and collagen domain containing |
multiple interactions |
ISO |
[2,2-bis(4-glycidyloxyphenyl)propane co-treated with Cytarabine] results in decreased expression of ADIPOQ mRNA |
CTD |
PMID:23264188 |
|
NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564
|
|
G |
Afap1l2 |
actin filament associated protein 1-like 2 |
decreases expression |
ISO |
Cytarabine results in decreased expression of AFAP1L2 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 1:255,964,238...256,060,828
Ensembl chr 1:255,964,238...256,060,820
|
|
G |
Ahi1 |
Abelson helper integration site 1 |
increases expression |
ISO |
Cytarabine results in increased expression of AHI1 protein alternative form |
CTD |
PMID:19379585 |
|
NCBI chr 1:15,762,485...15,891,213
Ensembl chr 1:15,762,462...15,891,041
|
|
G |
Ahnak |
AHNAK nucleoprotein |
decreases expression |
ISO |
Cytarabine results in decreased expression of AHNAK mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 1:205,882,225...205,970,934
Ensembl chr 1:205,882,273...205,970,926
|
|
G |
Aif1l |
allograft inflammatory factor 1-like |
increases expression |
ISO |
Cytarabine results in increased expression of AIF1L mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 3:15,229,476...15,254,033
Ensembl chr 3:15,229,524...15,254,023
|
|
G |
Akr1b8 |
aldo-keto reductase family 1, member B8 |
decreases expression |
ISO |
Cytarabine results in decreased expression of AKR1B15 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 4:62,997,241...63,009,815
Ensembl chr 4:62,997,161...63,010,097
|
|
G |
Alpk2 |
alpha-kinase 2 |
decreases expression |
ISO |
Cytarabine results in decreased expression of ALPK2 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr18:58,775,603...58,906,150
Ensembl chr18:58,775,605...58,906,258
|
|
G |
Angptl2 |
angiopoietin-like 2 |
decreases expression |
ISO |
Cytarabine results in decreased expression of ANGPTL2 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 3:16,517,185...16,547,024
Ensembl chr 3:16,517,420...16,548,178
|
|
G |
Anks1a |
ankyrin repeat and sterile alpha motif domain containing 1A |
decreases expression |
ISO |
Cytarabine results in decreased expression of ANKS1A mRNA |
CTD |
PMID:21198554 |
|
NCBI chr20:5,963,658...6,117,139
Ensembl chr20:5,963,678...6,117,148
|
|
G |
Ano8 |
anoctamin 8 |
increases expression |
ISO |
Cytarabine results in increased expression of ANO8 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr16:18,163,853...18,173,248
Ensembl chr16:18,163,843...18,173,545
|
|
G |
Anxa2 |
annexin A2 |
decreases expression increases expression |
ISO |
Cytarabine results in decreased expression of ANXA2 mRNA Cytarabine results in increased expression of ANXA2 mRNA |
CTD |
PMID:12165291 PMID:21198554 |
|
NCBI chr 8:70,105,268...70,141,663
Ensembl chr 8:70,105,253...70,141,658
|
|
G |
Anxa6 |
annexin A6 |
decreases expression |
ISO |
Cytarabine results in decreased expression of ANXA6 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr10:39,101,395...39,156,483
Ensembl chr10:39,097,109...39,156,433
|
|
G |
Anxa8 |
annexin A8 |
decreases expression |
ISO |
Cytarabine results in decreased expression of ANXA8 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr16:9,397,144...9,412,072
Ensembl chr16:9,397,113...9,412,043
|
|
G |
Aplnr |
apelin receptor |
decreases expression |
ISO |
Cytarabine results in decreased expression of APLNR mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 3:70,217,407...70,221,052
Ensembl chr 3:70,217,385...70,221,050
|
|
G |
Aqp1 |
aquaporin 1 |
decreases expression |
ISO |
Cytarabine results in decreased expression of AQP1 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 4:84,482,512...84,494,690
Ensembl chr 4:84,482,512...84,494,690
|
|
G |
Arg2 |
arginase 2 |
decreases expression |
ISO |
Cytarabine results in decreased expression of ARG2 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 6:97,936,002...97,961,379
Ensembl chr 6:97,936,002...97,961,378
|
|
G |
Arhgap44 |
Rho GTPase activating protein 44 |
decreases expression |
ISO |
Cytarabine results in decreased expression of ARHGAP44 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr10:49,655,583...49,822,876
Ensembl chr10:49,655,584...49,824,297
|
|
G |
Arhgdib |
Rho GDP dissociation inhibitor beta |
decreases expression |
ISO |
Cytarabine results in decreased expression of ARHGDIB mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 4:169,822,951...169,841,884
Ensembl chr 4:169,822,952...169,841,658
|
|
G |
Arhgef3 |
Rho guanine nucleotide exchange factor 3 |
decreases expression |
ISO |
Cytarabine results in decreased expression of ARHGEF3 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr16:2,301,573...2,581,951
Ensembl chr16:2,300,138...2,581,945
|
|
G |
Arl6ip5 |
ARF like GTPase 6 interacting protein 5 |
increases expression |
ISO |
Cytarabine results in increased expression of ARL6IP5 protein |
CTD |
PMID:16430862 |
|
NCBI chr 4:129,810,650...129,838,628
Ensembl chr 4:129,810,645...129,838,608
|
|
G |
Art4 |
ADP-ribosyltransferase 4 |
decreases expression |
ISO |
Cytarabine results in decreased expression of ART4 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 4:169,740,331...169,751,571
Ensembl chr 4:169,740,331...169,750,665
|
|
G |
Art5 |
ADP-ribosyltransferase 5 |
decreases expression |
ISO |
Cytarabine results in decreased expression of ART5 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 1:156,473,362...156,483,324
Ensembl chr 1:156,473,362...156,483,324
|
|
G |
Atf3 |
activating transcription factor 3 |
decreases expression increases expression |
ISO |
Cytarabine results in decreased expression of ATF3 mRNA Cytarabine results in increased expression of ATF3 mRNA |
CTD |
PMID:21198554 PMID:33770205 |
|
NCBI chr13:102,751,278...102,800,520
Ensembl chr13:102,751,321...102,764,631
|
|
G |
Atl1 |
atlastin GTPase 1 |
increases expression |
ISO |
Cytarabine results in increased expression of ATL1 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 6:88,377,168...88,475,242
Ensembl chr 6:88,377,239...88,475,204
|
|
G |
Atn1 |
atrophin 1 |
increases expression |
ISO |
Cytarabine results in increased expression of ATN1 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 4:157,554,287...157,568,092
Ensembl chr 4:157,551,276...157,568,132
|
|
G |
Atp10d |
ATPase phospholipid transporting 10D (putative) |
increases expression |
ISO |
Cytarabine results in increased expression of ATP10D mRNA |
CTD |
PMID:19194470 |
|
NCBI chr14:35,911,728...36,012,549
Ensembl chr14:35,912,141...36,012,564
|
|
G |
Atp1b1 |
ATPase Na+/K+ transporting subunit beta 1 |
decreases expression |
ISO |
Cytarabine results in decreased expression of ATP1B1 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr13:76,786,580...76,807,096
Ensembl chr13:76,786,578...76,807,459
|
|
G |
Atp7b |
ATPase copper transporting beta |
decreases expression |
ISO |
Cytarabine results in decreased expression of ATP7B mRNA |
CTD |
PMID:21198554 |
|
NCBI chr16:69,952,286...70,024,404
Ensembl chr16:69,951,778...70,023,636
|
|
G |
Atp8b4 |
ATPase phospholipid transporting 8B4 (putative) |
decreases expression |
ISO |
Cytarabine results in decreased expression of ATP8B4 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 3:113,554,979...113,757,635
Ensembl chr 3:113,556,192...113,757,225
|
|
G |
Axl |
Axl receptor tyrosine kinase |
decreases expression |
ISO |
Cytarabine results in decreased expression of AXL mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 1:81,265,088...81,296,278
Ensembl chr 1:81,265,088...81,296,265
|
|
G |
B2m |
beta-2 microglobulin |
increases expression |
ISO |
Cytarabine results in increased expression of B2M protein |
CTD |
PMID:11096300 |
|
NCBI chr 3:109,095,740...109,101,764
Ensembl chr 3:109,095,729...109,101,766
|
|
G |
B4galt7 |
beta-1,4-galactosyltransferase 7 |
decreases expression |
ISO |
Cytarabine results in decreased expression of B4GALT7 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr17:9,018,514...9,027,591
Ensembl chr17:9,018,935...9,027,573
|
|
G |
Bag3 |
BAG cochaperone 3 |
decreases expression |
ISO |
Cytarabine results in decreased expression of BAG3 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 1:183,103,038...183,126,862
Ensembl chr 1:183,102,871...183,126,858
|
|
G |
Baiap2l1 |
BAR/IMD domain containing adaptor protein 2 like 1 |
decreases expression |
ISO |
Cytarabine results in decreased expression of BAIAP2L1 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr12:10,250,434...10,339,937
Ensembl chr12:10,250,473...10,339,928
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
increases expression |
EXP ISO |
Cytarabine results in increased expression of BAX mRNA [Cytarabine results in increased expression of TP53 protein] which results in increased expression of BAX protein; Cytarabine results in increased expression of BAX protein |
CTD |
PMID:10200513 PMID:15203180 PMID:16129037 PMID:17490525 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bbc3 |
Bcl-2 binding component 3 |
affects response to substance |
ISO |
BBC3 protein affects the susceptibility to Cytarabine |
CTD |
PMID:20477944 |
|
NCBI chr 1:77,013,281...77,022,509
Ensembl chr 1:77,014,543...77,022,509
|
|
G |
Bcar3 |
BCAR3 adaptor protein, NSP family member |
decreases expression |
ISO |
Cytarabine results in decreased expression of BCAR3 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 2:210,525,260...210,638,674
Ensembl chr 2:210,525,260...210,638,798
|
|
G |
Bche |
butyrylcholinesterase |
increases activity multiple interactions |
EXP |
Cytarabine results in increased activity of BCHE protein betanin inhibits the reaction [Cytarabine results in increased activity of BCHE protein] |
CTD |
PMID:36419121 |
|
NCBI chr 2:158,308,674...158,401,148
Ensembl chr 2:158,307,584...158,401,148
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions increases degradation decreases expression |
ISO |
[Doxorubicin co-treated with Dexamethasone co-treated with Vincristine co-treated with Cytarabine co-treated with Mercaptopurine co-treated with Methotrexate co-treated with Cyclophosphamide co-treated with Enzymes and Coenzymes] results in increased expression of BCL2 protein; BCL2 protein inhibits the reaction [Cytarabine results in increased cleavage of and results in increased activity of CASP3 protein]; BCL2 protein inhibits the reaction [Cytarabine results in increased degradation of PARP1 protein]; edelfosine promotes the reaction [Cytarabine results in decreased expression of BCL2 protein] Cytarabine results in increased degradation of BCL2 protein Cytarabine results in decreased expression of BCL2 mRNA; Cytarabine results in decreased expression of BCL2 protein |
CTD |
PMID:1450413 PMID:8840993 PMID:9295281 PMID:12853972 PMID:16129037 PMID:17490525 PMID:21182165 More...
|
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
multiple interactions |
ISO |
BCL2L1 protein inhibits the reaction [Cytarabine results in increased cleavage of and results in increased activity of CASP3 protein]; BCL2L1 protein inhibits the reaction [Cytarabine results in increased degradation of PARP1 protein] |
CTD |
PMID:8840993 |
|
NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479 Ensembl chr 1:141,253,523...141,303,479
|
|
G |
Bhlhe22 |
basic helix-loop-helix family, member e22 |
increases expression |
ISO |
Cytarabine results in increased expression of BHLHE22 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 2:100,486,400...100,489,510
Ensembl chr 2:100,486,400...100,489,510
|
|
G |
Bid |
BH3 interacting domain death agonist |
multiple interactions |
ISO |
[Cytarabine co-treated with TNFSF10 protein] results in increased expression of BID protein |
CTD |
PMID:12780785 |
|
NCBI chr 4:154,113,198...154,136,353
Ensembl chr 4:154,113,198...154,134,720
|
|
G |
Bin2 |
bridging integrator 2 |
increases expression |
ISO |
Cytarabine results in increased expression of BIN2 mRNA |
CTD |
PMID:19194470 |
|
NCBI chr 7:131,742,001...131,768,208
Ensembl chr 7:131,742,002...131,786,285
|
|
G |
Bmp4 |
bone morphogenetic protein 4 |
decreases expression |
ISO |
Cytarabine results in decreased expression of BMP4 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr15:19,618,538...19,633,494
Ensembl chr15:19,618,542...19,623,306
|
|
G |
Bmp5 |
bone morphogenetic protein 5 |
decreases expression |
ISO |
Cytarabine results in decreased expression of BMP5 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 8:76,517,164...76,639,925
Ensembl chr 8:76,517,164...76,639,925
|
|
G |
Bnc1 |
basonuclin zinc finger protein 1 |
decreases expression |
ISO |
Cytarabine results in decreased expression of BNC1 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 1:135,917,676...135,943,333
Ensembl chr 1:135,917,687...135,943,333
|
|
G |
Bnc2 |
basonuclin zinc finger protein 2 |
decreases expression |
ISO |
Cytarabine results in decreased expression of BNC2 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 5:98,679,071...99,016,044
Ensembl chr 5:98,687,410...99,079,426
|
|
G |
Bora |
bora, aurora kinase A activator |
decreases expression |
ISO |
Cytarabine results in decreased expression of BORA mRNA |
CTD |
PMID:17374387 |
|
NCBI chr15:75,797,624...75,835,599
Ensembl chr15:75,797,891...75,821,322
|
|
G |
Bpnt2 |
3'(2'), 5'-bisphosphate nucleotidase 2 |
decreases expression |
ISO |
Cytarabine results in decreased expression of BPNT2 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 5:17,775,684...17,802,570
Ensembl chr 5:17,772,608...17,802,570
|
|
G |
Brca2 |
BRCA2, DNA repair associated |
increases expression |
ISO |
Cytarabine results in increased expression of BRCA2 mRNA |
CTD |
PMID:19194470 |
|
NCBI chr12:59,492...103,789
Ensembl chr12:59,819...100,567
|
|
G |
Bscl2 |
BSCL2 lipid droplet biogenesis associated, seipin |
increases expression |
ISO |
Cytarabine results in increased expression of BSCL2 mRNA |
CTD |
PMID:22003191 |
|
NCBI chr 1:205,731,828...205,743,430
Ensembl chr 1:205,733,872...205,743,421
|
|
G |
Bst2 |
bone marrow stromal cell antigen 2 |
decreases expression |
ISO |
Cytarabine results in decreased expression of BST2 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr16:18,216,605...18,220,979
Ensembl chr16:18,217,407...18,220,979
|
|
G |
Btg2 |
BTG anti-proliferation factor 2 |
increases expression |
ISO |
Cytarabine results in increased expression of BTG2 mRNA |
CTD |
PMID:21382384 |
|
NCBI chr13:45,531,881...45,535,642
Ensembl chr13:45,531,925...45,535,628
|
|
G |
C2cd2 |
C2 calcium-dependent domain containing 2 |
decreases expression |
ISO |
Cytarabine results in decreased expression of C2CD2 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr11:37,225,321...37,289,741
Ensembl chr11:37,227,415...37,289,739
|
|
G |
C3ar1 |
complement C3a receptor 1 |
increases expression |
ISO |
Cytarabine results in increased expression of C3AR1 mRNA |
CTD |
PMID:19194470 |
|
NCBI chr 4:156,074,747...156,084,680
Ensembl chr 4:156,075,389...156,084,701
|
|
G |
Cab39l |
calcium binding protein 39-like |
decreases expression |
ISO |
Cytarabine results in decreased expression of CAB39L mRNA |
CTD |
PMID:21198554 |
|
NCBI chr15:33,606,588...33,710,518
Ensembl chr15:33,606,694...33,743,545
|
|
G |
Calb1 |
calbindin 1 |
decreases expression |
EXP |
Cytarabine results in decreased expression of CALB1 protein |
CTD |
PMID:22212197 |
|
NCBI chr 5:29,375,624...29,402,532
Ensembl chr 5:29,375,642...29,402,431
|
|
G |
Calb2 |
calbindin 2 |
decreases expression |
ISO |
Cytarabine results in decreased expression of CALB2 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr19:38,114,435...38,141,438
Ensembl chr19:38,114,424...38,141,438
|
|
G |
Calcr |
calcitonin receptor |
increases response to substance |
ISO |
CALCR results in increased susceptibility to Cytarabine |
CTD |
PMID:21755009 |
|
NCBI chr 4:31,661,270...31,736,392
Ensembl chr 4:31,661,273...31,736,392
|
|
G |
Camk2n1 |
calcium/calmodulin-dependent protein kinase II inhibitor 1 |
increases expression |
ISO |
Cytarabine results in increased expression of CAMK2N1 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 5:150,674,819...150,676,600
Ensembl chr 5:150,673,507...150,676,600
|
|
G |
Capn1 |
calpain 1 |
decreases expression |
ISO |
Cytarabine results in decreased expression of CAPN1 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 1:203,275,912...203,300,848
Ensembl chr 1:203,277,344...203,300,177
|
|
G |
Car12 |
carbonic anhydrase 12 |
decreases expression |
ISO |
Cytarabine results in decreased expression of CA12 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 8:67,274,739...67,330,428
Ensembl chr 8:67,274,359...67,330,440
|
|
G |
Carmil1 |
capping protein regulator and myosin 1 linker 1 |
decreases expression |
ISO |
Cytarabine results in decreased expression of CARMIL1 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr17:40,807,921...41,088,326
Ensembl chr17:40,808,389...41,088,326
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases activity increases expression |
ISO EXP |
[Cytarabine co-treated with TNFSF10 protein] results in increased activity of CASP3 protein; BCL2 protein inhibits the reaction [Cytarabine results in increased cleavage of and results in increased activity of CASP3 protein]; BCL2L1 protein inhibits the reaction [Cytarabine results in increased cleavage of and results in increased activity of CASP3 protein]; Cytarabine results in increased cleavage of and results in increased activity of CASP3 protein Cytarabine results in increased activity of CASP3 protein Cytarabine results in increased expression of CASP3 protein |
CTD |
PMID:8840993 PMID:12780785 PMID:12781215 PMID:14766721 PMID:22212197 PMID:25003661 More...
|
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp8 |
caspase 8 |
multiple interactions |
ISO |
[Cytarabine co-treated with TNFSF10 protein] results in increased activity of CASP8 protein; Cytarabine promotes the reaction [TNFSF10 protein results in increased activity of CASP8 protein]; Cytarabine results in increased expression of and results in increased cleavage of CASP8 protein |
CTD |
PMID:12780785 PMID:18549619 PMID:22010212 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Cat |
catalase |
multiple interactions decreases expression |
EXP |
Thioctic Acid inhibits the reaction [Cytarabine results in decreased expression of CAT protein] |
CTD |
PMID:33225757 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Cavin1 |
caveolae associated protein 1 |
decreases expression |
ISO |
Cytarabine results in decreased expression of CAVIN1 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr10:85,884,100...85,896,136
Ensembl chr10:85,889,036...85,896,120
|
|
G |
Cavin3 |
caveolae associated protein 3 |
decreases expression |
ISO |
Cytarabine results in decreased expression of CAVIN3 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 1:159,826,549...159,828,138
Ensembl chr 1:159,826,549...159,828,161
|
|
G |
Ccdc102a |
coiled-coil domain containing 102A |
decreases expression |
ISO |
Cytarabine results in decreased expression of CCDC102A mRNA |
CTD |
PMID:21198554 |
|
NCBI chr19:10,102,543...10,118,657
Ensembl chr19:10,103,361...10,118,657
|
|
G |
Ccdc112 |
coiled-coil domain containing 112 |
increases expression |
ISO |
Cytarabine results in increased expression of CCDC112 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr18:38,998,139...39,032,329
Ensembl chr18:38,998,139...39,032,329
|
|
G |
Ccdc15 |
coiled-coil domain containing 15 |
increases expression |
ISO |
Cytarabine results in increased expression of CCDC15 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 8:36,991,147...37,068,849
Ensembl chr 8:36,998,867...37,068,919
|
|
G |
Cckbr |
cholecystokinin B receptor |
decreases expression |
ISO |
Cytarabine results in decreased expression of CCKBR mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 1:159,771,733...159,781,738
Ensembl chr 1:159,771,733...159,814,881
|
|
G |
Ccnd3 |
cyclin D3 |
decreases expression |
ISO |
Cytarabine results in decreased expression of CCND3 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 9:13,394,161...13,400,341
Ensembl chr 9:13,394,169...13,489,371
|
|
G |
Ccne2 |
cyclin E2 |
increases expression |
ISO |
Cytarabine results in increased expression of CCNE2 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 5:24,285,078...24,298,258
Ensembl chr 5:24,284,922...24,297,632
|
|
G |
Ccng1 |
cyclin G1 |
increases expression |
EXP |
Cytarabine results in increased expression of CCNG1 mRNA |
CTD |
PMID:14766721 PMID:15203180 |
|
NCBI chr10:25,176,231...25,182,604
Ensembl chr10:25,176,234...25,181,641
|
|
G |
Cd44 |
CD44 molecule |
decreases expression |
ISO |
Cytarabine results in decreased expression of CD44 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 3:89,155,850...89,244,615
Ensembl chr 3:89,157,058...89,244,620
|
|
G |
Cd8a |
CD8 subunit alpha |
increases expression |
ISO |
Cytarabine results in increased expression of CD8A mRNA |
CTD |
PMID:19194470 |
|
NCBI chr 4:103,365,804...103,370,041
Ensembl chr 4:103,365,804...103,370,040
|
|
G |
Cdc42ep5 |
CDC42 effector protein 5 |
decreases expression |
ISO |
Cytarabine results in decreased expression of CDC42EP5 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 1:70,035,921...70,038,990
|
|
G |
Cdca8 |
cell division cycle associated 8 |
decreases expression |
ISO |
Cytarabine results in decreased expression of CDCA8 mRNA |
CTD |
PMID:17374387 |
|
NCBI chr 5:137,176,414...137,198,686
Ensembl chr 5:137,176,417...137,198,629
|
|
G |
Cdh11 |
cadherin 11 |
decreases expression |
ISO |
Cytarabine results in decreased expression of CDH11 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr19:2,148,447...2,305,754
Ensembl chr19:2,148,458...2,304,272
|
|
G |
Cdh3 |
cadherin 3 |
decreases expression |
ISO |
Cytarabine results in decreased expression of CDH3 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr19:34,393,596...34,444,084
Ensembl chr19:34,393,727...34,444,084
|
|
G |
Cdk5r1 |
cyclin-dependent kinase 5 regulatory subunit 1 |
increases expression |
ISO |
Cytarabine results in increased expression of CDK5R1 mRNA |
CTD |
PMID:33770205 |
|
NCBI chr10:65,484,266...65,485,467
Ensembl chr10:65,483,941...65,488,456
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
multiple interactions increases expression |
ISO EXP |
[fludarabine co-treated with Cytarabine co-treated with Docetaxel] results in increased expression of CDKN1A protein; Caffeine inhibits the reaction [Cytarabine results in increased expression of CDKN1A protein] Cytarabine results in increased expression of CDKN1A mRNA; Cytarabine results in increased expression of CDKN1A protein |
CTD |
PMID:9703875 PMID:14766721 PMID:15203180 PMID:17977830 PMID:33770205 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cdkn1c |
cyclin-dependent kinase inhibitor 1C |
decreases expression |
ISO |
Cytarabine results in decreased expression of CDKN1C mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 1:198,655,394...198,658,097
Ensembl chr 1:198,655,407...198,658,048
|
|
G |
Cebpd |
CCAAT/enhancer binding protein delta |
decreases expression |
ISO |
Cytarabine results in decreased expression of CEBPD mRNA |
CTD |
PMID:21198554 |
|
NCBI chr11:84,764,670...84,765,808
Ensembl chr11:84,764,565...84,765,829
|
|
G |
Celf3 |
CUGBP, Elav-like family member 3 |
increases expression |
ISO |
Cytarabine results in increased expression of CELF3 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 2:182,116,034...182,130,163
Ensembl chr 2:182,116,073...182,130,163
|
|
G |
Cemip |
cell migration inducing hyaluronidase 1 |
decreases expression |
ISO |
Cytarabine results in decreased expression of CEMIP mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 1:137,906,921...138,062,430
Ensembl chr 1:137,908,920...138,062,415
|
|
G |
Chat |
choline O-acetyltransferase |
increases activity |
EXP |
Cytarabine results in increased activity of CHAT protein |
CTD |
PMID:2900045 |
|
NCBI chr16:7,657,362...7,717,093
Ensembl chr16:7,657,362...7,717,093
|
|
G |
Chn1 |
chimerin 1 |
decreases expression |
ISO |
Cytarabine results in decreased expression of CHN1 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 3:58,509,822...58,676,462
Ensembl chr 3:58,510,536...58,676,490
|
|
G |
Cited2 |
Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 2 |
decreases expression |
ISO |
Cytarabine results in decreased expression of CITED2 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 1:12,312,426...12,314,869
Ensembl chr 1:12,312,160...12,314,897
|
|
G |
Ckb |
creatine kinase B |
increases expression |
ISO |
Cytarabine results in increased expression of CKB mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 6:130,729,420...130,732,301
Ensembl chr 6:130,729,423...130,732,315
|
|
G |
Cks2 |
CDC28 protein kinase regulatory subunit 2 |
decreases expression |
ISO |
Cytarabine results in decreased expression of CKS2 mRNA |
CTD |
PMID:17374387 |
|
NCBI chr17:13,570,611...13,575,770
|
|
G |
Cldn15 |
claudin 15 |
decreases expression |
ISO |
Cytarabine results in decreased expression of CLDN15 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr12:19,698,167...19,708,419
Ensembl chr12:19,698,337...19,706,819
|
|
G |
Clec1b |
C-type lectin domain family 1, member B |
decreases expression |
ISO |
Cytarabine results in decreased expression of CLEC1B mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 4:162,847,978...162,856,291
Ensembl chr 4:162,848,010...162,856,291
|
|
G |
Cnih2 |
cornichon family AMPA receptor auxiliary protein 2 |
increases expression |
ISO |
Cytarabine results in increased expression of CNIH2 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 1:202,399,416...202,405,110
Ensembl chr 1:202,399,419...202,405,089
|
|
G |
Cnr1 |
cannabinoid receptor 1 |
increases expression |
ISO |
Cytarabine results in increased expression of CNR1 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 5:48,408,543...48,436,099
Ensembl chr 5:48,408,574...48,435,099
|
|
G |
Cntfr |
ciliary neurotrophic factor receptor |
increases expression |
ISO |
Cytarabine results in increased expression of CNTFR mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 5:56,823,448...56,861,049
Ensembl chr 5:56,823,965...56,841,392
|
|
G |
Cntrl |
centriolin |
increases expression |
ISO |
Cytarabine results in increased expression of CNTRL mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 3:18,428,147...18,500,362
Ensembl chr 3:18,428,103...18,500,380
|
|
G |
Cobll1 |
cordon-bleu WH2 repeat protein-like 1 |
decreases expression |
ISO |
Cytarabine results in decreased expression of COBLL1 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 3:49,753,260...49,915,168
Ensembl chr 3:49,753,262...49,915,194
|
|
G |
Col13a1 |
collagen type XIII alpha 1 chain |
decreases expression |
ISO |
Cytarabine results in decreased expression of COL13A1 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr20:29,783,965...29,924,116
Ensembl chr20:29,783,965...29,924,032
|
|
G |
Col18a1 |
collagen type XVIII alpha 1 chain |
decreases expression |
ISO |
Cytarabine results in decreased expression of COL18A1 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr20:11,474,104...11,582,593
Ensembl chr20:11,474,104...11,582,593
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
decreases expression |
ISO |
Cytarabine results in decreased expression of COL1A1 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624
|
|
G |
Col1a2 |
collagen type I alpha 2 chain |
decreases expression |
ISO |
Cytarabine results in decreased expression of COL1A2 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 4:32,563,938...32,598,868
Ensembl chr 4:32,563,381...32,598,867
|
|
G |
Col3a1 |
collagen type III alpha 1 chain |
decreases expression |
ISO |
Cytarabine results in decreased expression of COL3A1 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 9:47,374,611...47,410,547
Ensembl chr 9:47,374,593...47,410,547
|
|
G |
Col5a1 |
collagen type V alpha 1 chain |
decreases expression |
ISO |
Cytarabine results in decreased expression of COL5A1 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 3:11,208,429...11,356,715
Ensembl chr 3:11,208,512...11,354,588
|
|
G |
Col5a2 |
collagen type V alpha 2 chain |
decreases expression |
ISO |
Cytarabine results in decreased expression of COL5A2 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 9:47,448,741...47,598,134
Ensembl chr 9:47,448,736...47,598,154
|
|
G |
Col6a2 |
collagen type VI alpha 2 chain |
decreases expression |
ISO |
Cytarabine results in decreased expression of COL6A2 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr20:12,021,676...12,049,425
Ensembl chr20:12,021,767...12,057,564
|
|
G |
Col6a3 |
collagen type VI alpha 3 chain |
decreases expression |
ISO |
Cytarabine results in decreased expression of COL6A3 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 9:91,361,578...91,439,434
Ensembl chr 9:91,361,583...91,439,471
|
|
G |
Col9a1 |
collagen type IX alpha 1 chain |
increases expression |
ISO |
Cytarabine results in increased expression of COL9A1 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 9:26,585,034...26,668,222
Ensembl chr 9:26,585,034...26,668,213
|
|
G |
Colec12 |
collectin sub-family member 12 |
decreases expression |
ISO |
Cytarabine results in decreased expression of COLEC12 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr18:732,950...920,620
Ensembl chr18:732,950...920,618
|
|
G |
Cpz |
carboxypeptidase Z |
decreases expression |
ISO |
Cytarabine results in decreased expression of CPZ mRNA |
CTD |
PMID:21198554 |
|
NCBI chr14:75,223,692...75,246,946
Ensembl chr14:75,223,605...75,246,945
|
|
G |
Crabp1 |
cellular retinoic acid binding protein 1 |
increases expression |
ISO |
Cytarabine results in increased expression of CRABP1 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 8:55,138,363...55,159,360
Ensembl chr 8:55,151,285...55,159,360
|
|
G |
Crispld2 |
cysteine-rich secretory protein LCCL domain containing 2 |
decreases expression |
ISO |
Cytarabine results in decreased expression of CRISPLD2 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr19:48,053,153...48,111,485
Ensembl chr19:48,053,287...48,110,465
|
|
G |
Crtap |
cartilage associated protein |
decreases expression |
ISO |
Cytarabine results in decreased expression of CRTAP mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 8:114,047,929...114,067,636
Ensembl chr 8:114,047,933...114,067,631
|
|
G |
Cryab |
crystallin, alpha B |
decreases expression |
ISO |
Cytarabine results in decreased expression of CRYAB mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 8:51,093,441...51,099,161
Ensembl chr 8:51,093,441...51,099,157
|
|
G |
Csnk1d |
casein kinase 1, delta |
decreases expression |
ISO |
Cytarabine results in decreased expression of CSNK1D mRNA |
CTD |
PMID:21198554 |
|
NCBI chr10:106,221,992...106,256,620
Ensembl chr10:106,221,992...106,256,614
|
|
G |
Csrnp1 |
cysteine and serine rich nuclear protein 1 |
decreases expression |
ISO |
Cytarabine results in decreased expression of AXUD1 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 8:119,704,712...119,717,767
Ensembl chr 8:119,704,713...119,718,183
|
|
G |
Ctsh |
cathepsin H |
decreases expression |
ISO |
Cytarabine results in decreased expression of CTSH mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 8:90,608,941...90,627,824
Ensembl chr 8:90,608,941...90,627,824
|
|
G |
Ctsl |
cathepsin L |
decreases expression |
ISO |
Cytarabine results in decreased expression of CTSL mRNA |
CTD |
PMID:21198554 |
|
NCBI chr17:764,370...770,533
Ensembl chr17:764,309...770,548
|
|
G |
Cxcr4 |
C-X-C motif chemokine receptor 4 |
increases expression |
ISO |
Cytarabine results in increased expression of CXCR4 mRNA |
CTD |
PMID:19194470 PMID:21198554 |
|
NCBI chr13:40,077,976...40,081,883
Ensembl chr13:40,077,976...40,081,883
|
|
G |
Cyb5a |
cytochrome b5 type A |
decreases expression |
ISO |
Cytarabine results in decreased expression of CYB5A mRNA |
CTD |
PMID:21198554 |
|
NCBI chr18:78,213,067...78,245,677
Ensembl chr18:78,202,342...78,258,535 Ensembl chr18:78,202,342...78,258,535
|
|
G |
Cyb5d1 |
cytochrome b5 domain containing 1 |
decreases expression |
ISO |
Cytarabine results in decreased expression of CYB5D1 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr10:54,113,428...54,117,744
Ensembl chr10:54,113,438...54,117,911
|
|
G |
Cyb5r2 |
cytochrome b5 reductase 2 |
decreases expression |
ISO |
Cytarabine results in decreased expression of CYB5R2 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 1:161,655,862...161,664,359
Ensembl chr 1:161,655,864...161,664,097
|
|
G |
Cyba |
cytochrome b-245 alpha chain |
decreases expression |
ISO |
Cytarabine results in decreased expression of CYBA mRNA |
CTD |
PMID:21198554 |
|
NCBI chr19:50,487,598...50,495,669
Ensembl chr19:50,487,597...50,495,721
|
|
G |
Cyp27a1 |
cytochrome P450, family 27, subfamily a, polypeptide 1 |
decreases expression |
ISO |
Cytarabine results in decreased expression of CYP27A1 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 9:76,264,655...76,294,551
Ensembl chr 9:76,264,860...76,294,551
|
|
G |
Cyp4x1 |
cytochrome P450, family 4, subfamily x, polypeptide 1 |
decreases expression |
ISO |
Cytarabine results in decreased expression of CYP4X1 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 5:128,651,681...128,683,338
Ensembl chr 5:128,651,776...128,682,779
|
|
G |
Cyth1 |
cytohesin 1 |
increases expression |
ISO |
Cytarabine results in increased expression of CYTH1 mRNA |
CTD |
PMID:19194470 |
|
NCBI chr10:103,402,727...103,485,826
Ensembl chr10:103,366,145...103,485,760
|
|
G |
Dab2 |
DAB adaptor protein 2 |
decreases expression |
ISO |
Cytarabine results in decreased expression of DAB2 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 2:55,514,692...55,567,476
Ensembl chr 2:55,514,700...55,567,476
|
|
G |
Dalrd3 |
DALR anticodon binding domain containing 3 |
decreases expression |
ISO |
Cytarabine results in decreased expression of DALRD3 mRNA |
CTD |
PMID:19194470 |
|
NCBI chr 8:109,264,100...109,268,560
Ensembl chr 8:109,265,676...109,268,568
|
|
G |
Dbn1 |
drebrin 1 |
decreases expression |
ISO |
Cytarabine results in decreased expression of DBN1 mRNA |
CTD |
PMID:19194470 |
|
NCBI chr17:9,150,608...9,164,982
Ensembl chr17:9,150,659...9,164,984
|
|
G |
Dck |
deoxycytidine kinase |
affects binding decreases response to substance |
ISO EXP |
Cytarabine binds to DCK protein Cytarabine binds to Dck protein DCK gene polymorphism results in decreased susceptibility to Cytarabine |
CTD RGD |
PMID:1318170 PMID:18381442 PMID:7532033 |
RGD:2300399 |
NCBI chr14:19,305,218...19,326,247
Ensembl chr14:19,305,218...19,326,247
|
|
G |
Dcn |
decorin |
decreases expression |
ISO |
Cytarabine results in decreased expression of DCN mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 7:32,281,252...32,321,291
Ensembl chr 7:32,281,252...32,321,270
|
|
G |
Ddr2 |
discoidin domain receptor tyrosine kinase 2 |
decreases expression |
ISO |
Cytarabine results in decreased expression of DDR2 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr13:82,193,623...82,318,229
Ensembl chr13:82,195,463...82,317,363
|
|
G |
Dennd1a |
DENN domain containing 1A |
increases expression |
ISO |
Cytarabine results in increased expression of DENND1A mRNA |
CTD |
PMID:19194470 |
|
NCBI chr 3:21,564,749...22,052,057
Ensembl chr 3:21,564,749...22,052,062
|
|
G |
Deptor |
DEP domain containing MTOR-interacting protein |
decreases expression |
ISO |
Cytarabine results in decreased expression of DEPTOR mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 7:86,514,859...86,668,817
Ensembl chr 7:86,514,988...86,667,773
|
|
G |
Dhcr24 |
24-dehydrocholesterol reductase |
decreases expression |
ISO |
Cytarabine results in decreased expression of DHCR24 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 5:121,344,552...121,371,124
Ensembl chr 5:121,344,575...121,371,137
|
|
G |
Dhfr |
dihydrofolate reductase |
increases expression |
ISO |
Cytarabine results in increased expression of DHFR mRNA |
CTD |
PMID:19194470 |
|
NCBI chr 2:23,585,876...23,611,199
Ensembl chr 2:23,586,031...23,613,713
|
|
G |
Disp3 |
dispatched RND transporter family member 3 |
increases expression |
ISO |
Cytarabine results in increased expression of DISP3 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 5:158,672,015...158,720,806
Ensembl chr 5:158,672,015...158,720,806
|
|
G |
Dnah2 |
dynein, axonemal, heavy chain 2 |
decreases expression |
ISO |
Cytarabine results in decreased expression of DNAH2 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr10:54,142,648...54,268,901
Ensembl chr10:54,142,737...54,267,298
|
|
G |
Dok4 |
docking protein 4 |
decreases expression |
ISO |
Cytarabine results in decreased expression of DOK4 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr19:10,146,520...10,157,187
Ensembl chr19:10,146,474...10,158,203
|
|
G |
Dsc2 |
desmocollin 2 |
decreases expression |
ISO |
Cytarabine results in decreased expression of DSC2 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr18:11,450,392...11,482,476
Ensembl chr18:11,450,390...11,482,392
|
|
G |
Dsc3 |
desmocollin 3 |
decreases expression |
ISO |
Cytarabine results in decreased expression of DSC3 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr18:11,379,759...11,413,797
Ensembl chr18:11,377,347...11,413,797
|
|
G |
Dusp4 |
dual specificity phosphatase 4 |
decreases expression |
ISO |
Cytarabine results in decreased expression of DUSP4 mRNA |
CTD |
PMID:19194470 |
|
NCBI chr16:57,376,659...57,398,161
Ensembl chr16:57,377,229...57,398,138
|
|
G |
E2f8 |
E2F transcription factor 8 |
increases expression |
ISO |
Cytarabine results in increased expression of E2F8 mRNA |
CTD |
PMID:33770205 |
|
NCBI chr 1:98,565,717...98,584,265
Ensembl chr 1:98,565,717...98,584,098
|
|
G |
Edn1 |
endothelin 1 |
multiple interactions |
ISO |
EDN1 mutant form inhibits the reaction [VEGFC protein results in decreased susceptibility to Cytarabine] EDN1 mutant form affects the reaction [VEGFC protein results in decreased susceptibility to Cytarabine] |
CTD |
PMID:24184161 |
|
NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885
|
|
G |
Eef2 |
eukaryotic translation elongation factor 2 |
decreases expression |
ISO |
Cytarabine results in decreased expression of EEF2 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 7:8,533,248...8,538,518
Ensembl chr 7:8,533,116...8,559,183
|
|
G |
Efemp2 |
EGF containing fibulin extracellular matrix protein 2 |
decreases expression |
ISO |
Cytarabine results in decreased expression of EFEMP2 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 1:202,781,692...202,789,784
Ensembl chr 1:202,781,665...202,789,414
|
|
G |
Efhd1 |
EF-hand domain family, member D1 |
decreases expression |
ISO |
Cytarabine results in decreased expression of EFHD1 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 9:87,938,259...87,984,917
Ensembl chr 9:87,938,284...87,984,917
|
|
G |
Efna1 |
ephrin A1 |
decreases expression |
ISO |
Cytarabine results in decreased expression of EFNA1 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 2:174,681,676...174,689,061
Ensembl chr 2:174,681,682...174,690,866
|
|
G |
Egfl6 |
EGF-like-domain, multiple 6 |
decreases expression |
ISO |
Cytarabine results in decreased expression of EGFL6 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr X:27,884,087...27,942,044
Ensembl chr X:27,884,125...27,942,044
|
|
G |
Egflam |
EGF-like, fibronectin type III and laminin G domains |
decreases expression |
ISO |
Cytarabine results in decreased expression of EGFLAM mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 2:56,301,945...56,476,665
Ensembl chr 2:56,302,566...56,476,298
|
|
G |
Eif4h |
eukaryotic translation initiation factor 4H |
decreases expression |
ISO |
Cytarabine results in decreased expression of EIF4H mRNA |
CTD |
PMID:21198554 |
|
NCBI chr12:22,083,155...22,099,876
Ensembl chr12:22,082,835...22,099,876
|
|
G |
Eno3 |
enolase 3 |
decreases expression |
ISO |
Cytarabine results in decreased expression of ENO3 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr10:55,370,531...55,375,921
Ensembl chr10:55,366,975...55,375,921
|
|
G |
Entpd1 |
ectonucleoside triphosphate diphosphohydrolase 1 |
increases expression |
ISO |
Cytarabine results in increased expression of ENTPD1 mRNA |
CTD |
PMID:19194470 |
|
NCBI chr 1:239,425,515...239,552,323
Ensembl chr 1:239,425,430...239,552,317
|
|
G |
Exog |
exo/endonuclease G |
decreases expression |
ISO |
Cytarabine results in decreased expression of EXOG mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 8:119,184,974...119,204,819
Ensembl chr 8:119,185,136...119,204,672
|
|
G |
Ext2 |
exostosin glycosyltransferase 2 |
decreases expression |
ISO |
Cytarabine results in decreased expression of EXT2 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 3:79,665,414...79,798,077
Ensembl chr 3:79,665,415...79,798,059
|
|
G |
Ezr |
ezrin |
decreases expression |
ISO |
Cytarabine results in decreased expression of EZR mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 1:46,967,961...47,011,505
Ensembl chr 1:46,967,658...47,011,505
|
|
G |
F2 |
coagulation factor II, thrombin |
affects expression |
ISO |
Cytarabine affects the expression of F2 protein |
CTD |
PMID:12542493 |
|
NCBI chr 3:77,596,196...77,609,486
Ensembl chr 3:77,596,198...77,609,486
|
|
G |
Fabp7 |
fatty acid binding protein 7 |
increases expression |
ISO |
Cytarabine results in increased expression of FABP7 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr20:37,123,193...37,126,725
Ensembl chr20:37,123,193...37,126,880
|
|
G |
Fam111a |
FAM111 trypsin like peptidase A |
increases expression |
ISO |
Cytarabine results in increased expression of FAM111A mRNA |
CTD |
PMID:19194470 |
|
NCBI chr 1:209,640,865...209,656,551
Ensembl chr 1:209,640,953...209,656,547
|
|
G |
Fas |
Fas cell surface death receptor |
increases expression |
EXP ISO |
Cytarabine results in increased expression of FAS mRNA |
CTD |
PMID:14766721 PMID:15203180 PMID:33770205 |
|
NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591
|
|
G |
Fbln1 |
fibulin 1 |
decreases expression |
ISO |
Cytarabine results in decreased expression of FBLN1 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 7:116,310,582...116,390,075
Ensembl chr 7:116,310,582...116,390,075
|
|
G |
Fbxo2 |
F-box protein 2 |
decreases expression |
ISO |
Cytarabine results in decreased expression of FBXO2 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 5:158,592,926...158,598,355
Ensembl chr 5:158,592,925...158,598,355
|
|
G |
Fcgr2a |
Fc gamma receptor 2A |
increases expression |
ISO |
Cytarabine results in increased expression of FCGR2A mRNA |
CTD |
PMID:19194470 |
|
NCBI chr13:83,280,782...83,297,535
Ensembl chr13:83,280,784...83,295,967
|
|
G |
Flnc |
filamin C |
decreases expression |
ISO |
Cytarabine results in decreased expression of FLNC mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 4:58,034,088...58,061,882
Ensembl chr 4:58,034,189...58,061,844
|
|
G |
Flrt2 |
fibronectin leucine rich transmembrane protein 2 |
decreases expression |
ISO |
Cytarabine results in decreased expression of FLRT2 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 6:114,777,547...114,872,688
Ensembl chr 6:114,777,599...114,872,785
|
|
G |
Fmo1 |
flavin containing dimethylaniline monoxygenase 1 |
decreases expression |
ISO |
Cytarabine results in decreased expression of FMO1 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr13:75,182,184...75,214,439
Ensembl chr13:75,182,176...75,214,647
|
|
G |
Fmo4 |
flavin containing dimethylaniline monoxygenase 4 |
decreases expression |
ISO |
Cytarabine results in decreased expression of FMO4 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr13:75,154,683...75,172,874
Ensembl chr13:75,154,684...75,172,874
|
|
G |
Frzb |
frizzled-related protein |
decreases expression |
ISO |
Cytarabine results in decreased expression of FRZB mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 3:65,332,274...65,365,208
Ensembl chr 3:65,332,277...65,365,208
|
|
G |
Fsip1 |
fibrous sheath interacting protein 1 |
increases expression |
ISO |
Cytarabine results in increased expression of FSIP1 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 3:105,074,584...105,217,180
Ensembl chr 3:105,068,543...105,217,167
|
|
G |
Fyb2 |
FYN binding protein 2 |
decreases expression |
ISO |
Cytarabine results in decreased expression of FYB2 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 5:119,677,116...119,800,911
Ensembl chr 5:119,677,204...119,800,910
|
|
G |
Fyn |
FYN proto-oncogene, Src family tyrosine kinase |
increases expression |
ISO |
Cytarabine results in increased expression of FYN mRNA |
CTD |
PMID:21198554 |
|
NCBI chr20:42,767,733...42,960,903
Ensembl chr20:42,766,369...42,959,911
|
|
G |
Gabarapl1 |
GABA type A receptor associated protein like 1 |
decreases expression |
ISO |
Cytarabine results in decreased expression of GABARAPL1 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 4:162,980,309...162,989,452
Ensembl chr 4:162,980,249...162,989,450
|
|
G |
Gabrp |
gamma-aminobutyric acid type A receptor subunit pi |
increases expression |
ISO |
Cytarabine results in increased expression of GABRP mRNA |
CTD |
PMID:21198554 |
|
NCBI chr10:18,143,031...18,169,595
Ensembl chr10:18,143,038...18,169,516
|
|
G |
Gadd45a |
growth arrest and DNA-damage-inducible, alpha |
increases expression |
ISO |
Cytarabine results in increased expression of GADD45A mRNA |
CTD |
PMID:33770205 |
|
NCBI chr 4:96,154,789...96,157,091
Ensembl chr 4:96,154,789...96,157,115
|
|
G |
Galnt10 |
polypeptide N-acetylgalactosaminyltransferase 10 |
decreases expression |
ISO |
Cytarabine results in decreased expression of GALNT10 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr10:41,821,216...41,967,618
Ensembl chr10:41,820,158...41,967,013
|
|
G |
Gap43 |
growth associated protein 43 |
increases expression |
ISO |
Cytarabine results in increased expression of GAP43 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr11:58,376,371...58,470,047
Ensembl chr11:58,376,371...58,470,045
|
|
G |
Gapdh |
glyceraldehyde-3-phosphate dehydrogenase |
decreases activity affects localization increases response to substance |
ISO |
Cytarabine results in decreased activity of GAPDH protein Cytarabine affects the localization of GAPDH protein GAPDH protein results in increased susceptibility to Cytarabine |
CTD |
PMID:19628630 |
|
NCBI chr 4:157,962,312...157,967,158
Ensembl chr 4:157,962,343...157,966,235
|
|
G |
Gata5 |
GATA binding protein 5 |
decreases expression |
ISO |
Cytarabine results in decreased expression of GATA5 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 3:167,418,563...167,426,751
Ensembl chr 3:167,418,565...167,426,751
|
|
G |
Gbp4 |
guanylate binding protein 4 |
decreases expression |
ISO |
Cytarabine results in decreased expression of GBP4 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 2:231,304,910...231,318,883
Ensembl chr 2:231,305,244...231,318,879
|
|
G |
Gca |
grancalcin |
decreases expression |
ISO |
Cytarabine results in decreased expression of GCA mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 3:47,297,320...47,329,913
Ensembl chr 3:47,297,383...47,328,581
|
|
G |
Gcnt2 |
glucosaminyl (N-acetyl) transferase 2 |
decreases expression |
ISO |
Cytarabine results in decreased expression of GCNT2 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr17:23,796,859...23,901,625
Ensembl chr17:23,796,859...23,901,611
|
|
G |
Ghr |
growth hormone receptor |
decreases expression |
ISO |
Cytarabine results in decreased expression of GHR mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 2:52,541,452...52,804,960
Ensembl chr 2:52,542,594...52,804,735
|
|
G |
Gls |
glutaminase |
decreases expression |
ISO |
Cytarabine results in decreased expression of GLS mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 9:49,344,616...49,416,900
Ensembl chr 9:49,344,781...49,416,900
|
|
G |
Gnb3 |
G protein subunit beta 3 |
decreases expression |
ISO |
Cytarabine results in decreased expression of GNB3 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 4:157,639,468...157,645,171
Ensembl chr 4:157,639,469...157,645,173
|
|
G |
Gper1 |
G protein-coupled estrogen receptor 1 |
decreases expression |
ISO |
Cytarabine results in decreased expression of GPER1 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr12:15,217,217...15,222,679
Ensembl chr12:15,217,442...15,221,889
|
|
G |
Gpm6a |
glycoprotein m6a |
increases expression |
ISO |
Cytarabine results in increased expression of GPM6A mRNA |
CTD |
PMID:21198554 |
|
NCBI chr16:36,641,282...36,973,377
Ensembl chr16:36,641,284...36,973,475
|
|
G |
Gpr19 |
G protein-coupled receptor 19 |
increases expression |
ISO |
Cytarabine results in increased expression of GPR19 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 4:167,710,944...167,739,232
Ensembl chr 4:167,710,666...167,741,036
|
|
G |
Gpr83 |
G protein-coupled receptor 83 |
decreases expression |
ISO |
Cytarabine results in decreased expression of GPR83 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 8:11,693,540...11,704,028
Ensembl chr 8:11,693,540...11,704,028
|
|
G |
Gprc5c |
G protein-coupled receptor, class C, group 5, member C |
decreases expression |
ISO |
Cytarabine results in decreased expression of GPRC5C mRNA |
CTD |
PMID:21198554 |
|
NCBI chr10:99,886,900...99,908,928
Ensembl chr10:99,887,077...99,908,926
|
|
G |
Gria2 |
glutamate ionotropic receptor AMPA type subunit 2 |
increases expression |
ISO |
Cytarabine results in increased expression of GRIA2 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 2:165,949,379...166,069,510
Ensembl chr 2:165,947,521...166,069,510
|
|
G |
Grk5 |
G protein-coupled receptor kinase 5 |
increases expression |
ISO |
Cytarabine results in increased expression of GRK5 mRNA |
CTD |
PMID:19194470 |
|
NCBI chr 1:260,028,269...260,223,699
Ensembl chr 1:260,028,242...260,218,701
|
|
G |
Grpr |
gastrin releasing peptide receptor |
decreases expression |
ISO |
Cytarabine results in decreased expression of GRPR mRNA |
CTD |
PMID:21198554 |
|
NCBI chr X:30,998,425...31,038,442
Ensembl chr X:30,998,416...31,038,442
|
|
G |
Gstcd |
glutathione S-transferase, C-terminal domain containing |
increases expression |
ISO |
Cytarabine results in increased expression of GSTCD mRNA |
CTD |
PMID:19194470 |
|
NCBI chr 2:221,499,732...221,591,888
Ensembl chr 2:221,499,083...221,591,857
|
|
G |
Gstm1 |
glutathione S-transferase mu 1 |
affects response to substance |
ISO |
GSTM1 gene polymorphism affects the susceptibility to Cytarabine |
CTD |
PMID:15713801 |
|
NCBI chr 2:195,649,845...195,655,402
Ensembl chr 2:195,649,845...195,655,411
|
|
G |
Gtpbp1 |
GTP binding protein 1 |
increases expression |
ISO |
Cytarabine results in increased expression of GTPBP1 mRNA |
CTD |
PMID:19194470 |
|
NCBI chr 7:111,248,254...111,272,705
Ensembl chr 7:111,248,254...111,272,705
|
|
G |
Gucy1a1 |
guanylate cyclase 1 soluble subunit alpha 1 |
decreases expression |
ISO |
Cytarabine results in decreased expression of GUCY1A1 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 2:167,418,615...167,482,293
Ensembl chr 2:167,418,640...167,481,671
|
|
G |
H1f2 |
H1.2 linker histone, cluster member |
decreases expression |
ISO |
Cytarabine results in decreased expression of H1-2 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr17:41,391,106...41,392,597
Ensembl chr17:41,388,477...41,392,635
|
|
G |
H2aj |
H2A.J histone |
decreases expression |
ISO |
Cytarabine results in decreased expression of H2AJ mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 4:169,675,718...169,676,202
Ensembl chr 4:169,675,752...169,677,006
|
|
G |
H2ax |
H2A.X variant histone |
increases phosphorylation |
ISO |
Cytarabine results in increased phosphorylation of H2AX protein |
CTD |
PMID:19628630 PMID:34510228 |
|
NCBI chr 8:44,671,907...44,673,262
Ensembl chr 8:44,671,786...44,673,239 Ensembl chr 4:44,671,786...44,673,239
|
|
G |
Hand1 |
heart and neural crest derivatives expressed 1 |
decreases expression |
ISO |
Cytarabine results in decreased expression of HAND1 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr10:42,006,646...42,009,213
Ensembl chr10:42,006,651...42,009,213
|
|
G |
Hand2 |
heart and neural crest derivatives expressed 2 |
decreases expression |
ISO |
Cytarabine results in decreased expression of HAND2 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr16:32,917,448...32,920,791
Ensembl chr16:32,917,823...32,919,891
|
|
G |
Hapln1 |
hyaluronan and proteoglycan link protein 1 |
decreases expression |
ISO |
Cytarabine results in decreased expression of HAPLN1 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 2:20,631,640...20,696,388
Ensembl chr 2:20,631,640...20,693,777
|
|
G |
Has2 |
hyaluronan synthase 2 |
decreases expression |
ISO |
Cytarabine results in decreased expression of HAS2 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 7:88,113,326...88,139,337
Ensembl chr 7:88,113,326...88,128,933
|
|
G |
Hcfc1r1 |
host cell factor C1 regulator 1 |
decreases expression |
ISO |
Cytarabine results in decreased expression of HCFC1R1 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr10:12,705,139...12,706,852
Ensembl chr10:12,705,077...12,706,850
|
|
G |
Hes5 |
hes family bHLH transcription factor 5 |
increases expression |
ISO |
Cytarabine results in increased expression of HES5 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 5:165,522,138...165,523,684
Ensembl chr 5:165,522,234...165,523,001
|
|
G |
Hey1 |
hes-related family bHLH transcription factor with YRPW motif 1 |
decreases expression |
ISO |
Cytarabine results in decreased expression of HEY1 mRNA |
CTD |
PMID:33770205 |
|
NCBI chr 2:93,096,605...93,100,316
Ensembl chr 2:93,095,498...93,100,312
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
increases expression |
ISO |
Cytarabine results in increased expression of HIF1A mRNA |
CTD |
PMID:23264188 |
|
NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261
|
|
G |
Hmgb1 |
high mobility group box 1 |
decreases response to substance increases secretion |
ISO |
HMGB1 protein results in decreased susceptibility to Cytarabine Cytarabine results in increased secretion of HMGB1 protein |
CTD |
PMID:27807322 |
|
NCBI chr12:5,972,950...5,979,658
Ensembl chr12:5,901,586...5,978,565 Ensembl chr16:5,901,586...5,978,565
|
|
G |
Hmgcs2 |
3-hydroxy-3-methylglutaryl-CoA synthase 2 |
decreases expression |
ISO |
Cytarabine results in decreased expression of HMGCS2 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 2:185,875,609...185,903,505
Ensembl chr 2:185,875,616...185,902,130
|
|
G |
Hnrnpa3 |
heterogeneous nuclear ribonucleoprotein A3 |
decreases expression |
ISO |
Cytarabine results in decreased expression of HNRNPA3 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 3:60,578,574...60,588,755
Ensembl chr 3:60,578,673...60,588,306
|
|
G |
Hoxa2 |
homeobox A2 |
increases expression |
ISO |
Cytarabine results in increased expression of HOXA2 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 4:81,262,668...81,266,970
Ensembl chr 4:81,262,768...81,265,044
|
|
G |
Hoxa5 |
homeo box A5 |
increases expression |
ISO |
Cytarabine results in increased expression of HOXA5 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 4:81,302,341...81,306,234
Ensembl chr 4:81,302,353...81,306,234
|
|
G |
Hoxb4 |
homeo box B4 |
decreases expression |
ISO |
Cytarabine results in decreased expression of HOXB4 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr10:81,284,552...81,287,134
Ensembl chr10:81,284,552...81,287,128
|
|
G |
Hoxb6 |
homeo box B6 |
decreases expression |
ISO |
Cytarabine results in decreased expression of HOXB6 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr10:81,258,726...81,267,458
Ensembl chr10:81,265,056...81,267,449
|
|
G |
Hoxb8 |
homeo box B8 |
decreases expression |
ISO |
Cytarabine results in decreased expression of HOXB8 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr10:81,248,313...81,251,261
Ensembl chr10:81,248,887...81,250,638
|
|
G |
Hoxc6 |
homeo box C6 |
decreases expression |
ISO |
Cytarabine results in decreased expression of HOXC6 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 7:134,138,017...134,148,899
Ensembl chr 7:134,135,502...134,148,392
|
|
G |
Hoxc8 |
homeobox C8 |
decreases expression |
ISO |
Cytarabine results in decreased expression of HOXC8 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 7:134,127,937...134,130,503
Ensembl chr 7:134,127,913...134,130,503
|
|
G |
Hs3st1 |
heparan sulfate-glucosamine 3-sulfotransferase 1 |
decreases expression |
ISO |
Cytarabine results in decreased expression of HS3ST1 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr14:71,185,826...71,223,263
Ensembl chr14:71,185,682...71,223,248
|
|
G |
Hspa6l-ps1 |
heat shock protein family A (Hsp70) member 6 like, pseudogene 1 |
increases expression |
ISO |
Cytarabine results in increased expression of HSPA6 mRNA |
CTD |
PMID:19194470 |
|
NCBI chr13:83,273,176...83,274,317
|
|
G |
Htra1 |
HtrA serine peptidase 1 |
decreases expression |
ISO |
Cytarabine results in decreased expression of HTRA1 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 1:185,497,815...185,547,380
Ensembl chr 1:185,497,735...185,547,379
|
|
G |
Igfbp3 |
insulin-like growth factor binding protein 3 |
decreases expression |
ISO |
Cytarabine results in decreased expression of IGFBP3 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr14:82,056,347...82,064,083
Ensembl chr14:82,056,347...82,064,083
|
|
G |
Igfbp5 |
insulin-like growth factor binding protein 5 |
decreases expression |
ISO |
Cytarabine results in decreased expression of IGFBP5 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 9:74,452,371...74,464,953
Ensembl chr 9:74,448,382...74,465,156
|
|
G |
Il6 |
interleukin 6 |
increases expression |
ISO |
Cytarabine results in increased expression of IL6 protein |
CTD |
PMID:11745875 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Ina |
internexin neuronal intermediate filament protein, alpha |
increases expression |
ISO |
Cytarabine results in increased expression of INA mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 1:245,896,775...245,908,330
Ensembl chr 1:245,896,775...245,908,330
|
|
G |
Irx5 |
iroquois homeobox 5 |
increases expression |
ISO |
Cytarabine results in increased expression of IRX5 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr19:14,639,052...14,643,911
Ensembl chr19:14,624,225...14,642,318
|
|
G |
Itgb5 |
integrin subunit beta 5 |
decreases expression |
ISO |
Cytarabine results in decreased expression of ITGB5 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr11:66,828,428...66,944,231
Ensembl chr11:66,829,285...66,944,472
|
|
G |
Itm2c |
integral membrane protein 2C |
decreases expression |
ISO |
Cytarabine results in decreased expression of ITM2C mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 9:86,545,927...86,559,745
Ensembl chr 9:86,545,921...86,559,742
|
|
G |
Jam2 |
junctional adhesion molecule 2 |
increases expression |
ISO |
Cytarabine results in increased expression of JAM2 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr11:23,830,820...23,880,071
Ensembl chr11:23,831,106...23,880,063
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
increases expression |
ISO |
Cytarabine results in increased expression of JUN; Cytarabine results in increased expression of JUN mRNA |
CTD |
PMID:1450413 PMID:7949469 |
|
NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
|
|
G |
Kank4 |
KN motif and ankyrin repeat domains 4 |
decreases expression |
ISO |
Cytarabine results in decreased expression of KANK4 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 5:113,401,491...113,465,526
Ensembl chr 5:113,402,468...113,465,555
|
|
G |
Kcnn2 |
potassium calcium-activated channel subfamily N member 2 |
decreases expression |
ISO |
Cytarabine results in decreased expression of KCNN2 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr18:37,817,966...38,258,347
Ensembl chr18:37,817,957...38,258,347
|
|
G |
Kctd12 |
potassium channel tetramerization domain containing 12 |
decreases expression |
ISO |
Cytarabine results in decreased expression of KCTD12 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr15:79,800,078...79,806,017
Ensembl chr15:79,801,191...79,806,282
|
|
G |
Kdelr3 |
KDEL endoplasmic reticulum protein retention receptor 3 |
decreases expression |
ISO |
Cytarabine results in decreased expression of KDELR3 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 7:111,079,236...111,089,463
Ensembl chr 7:111,079,218...111,101,600
|
|
G |
Kiaa1671 |
KIAA1671 homolog |
decreases expression |
ISO |
Cytarabine results in decreased expression of KIAA1671 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr12:43,409,479...43,552,152
Ensembl chr12:43,411,069...43,552,157
|
|
G |
Kif15 |
kinesin family member 15 |
increases expression |
ISO |
Cytarabine results in increased expression of KIF15 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 8:122,601,888...122,672,750
Ensembl chr 8:122,601,897...122,672,750
|
|
G |
Klhl41 |
kelch-like family member 41 |
decreases expression |
ISO |
Cytarabine results in decreased expression of KLHL41 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 3:54,434,291...54,447,415
Ensembl chr 3:54,434,234...54,449,222
|
|
G |
Klk6 |
kallikrein related-peptidase 6 |
decreases expression |
ISO |
Cytarabine results in decreased expression of KLK6 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 1:94,278,863...94,286,136
Ensembl chr 1:94,280,340...94,286,121
|
|
G |
Kmo |
kynurenine 3-monooxygenase |
increases response to substance |
ISO |
KMO results in increased susceptibility to Cytarabine |
CTD |
PMID:21755009 |
|
NCBI chr13:87,557,080...87,589,334
Ensembl chr13:87,557,286...87,588,881
|
|
G |
Kmt2a |
lysine methyltransferase 2A |
increases response to substance |
ISO |
KMT2A gene mutant form results in increased susceptibility to Cytarabine |
CTD |
PMID:14712291 |
|
NCBI chr 8:45,116,763...45,193,320
Ensembl chr 8:45,118,814...45,193,181
|
|
G |
Kpna2 |
karyopherin subunit alpha 2 |
decreases expression |
ISO |
Cytarabine results in decreased expression of KPNA2 mRNA |
CTD |
PMID:17374387 |
|
NCBI chr10:91,933,951...91,946,115
Ensembl chr10:91,933,951...91,946,150
|
|
G |
Krt19 |
keratin 19 |
decreases expression |
ISO |
Cytarabine results in decreased expression of KRT19 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr10:85,075,835...85,080,552
Ensembl chr10:85,066,802...85,171,799
|
|
G |
Krt24 |
keratin 24 |
decreases expression |
ISO |
Cytarabine results in decreased expression of KRT24 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr10:84,232,163...84,237,299
Ensembl chr10:84,232,164...84,237,299
|
|
G |
Krt8 |
keratin 8 |
decreases expression |
ISO |
Cytarabine results in decreased expression of KRT8 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 7:133,124,203...133,131,656
Ensembl chr 7:133,124,203...133,131,728
|
|
G |
Kynu |
kynureninase |
decreases expression |
ISO |
Cytarabine results in decreased expression of KYNU mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 3:27,778,646...27,929,470
Ensembl chr 3:27,778,772...27,929,488
|
|
G |
Lbh |
LBH regulator of WNT signaling pathway |
decreases expression |
ISO |
Cytarabine results in decreased expression of LBH mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 6:22,569,238...22,593,056
Ensembl chr 6:22,568,834...22,593,079
|
|
G |
Lepr |
leptin receptor |
decreases expression |
ISO |
Cytarabine results in decreased expression of LEPR mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 5:116,294,409...116,477,904
Ensembl chr 5:116,289,823...116,475,908
|
|
G |
Lhfpl6 |
LHFPL tetraspan subfamily member 6 |
increases expression |
ISO |
Cytarabine results in increased expression of LHFPL6 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 2:137,126,485...137,324,442
Ensembl chr 2:137,126,509...137,324,443
|
|
G |
Limch1 |
LIM and calponin homology domains 1 |
increases expression |
ISO |
Cytarabine results in increased expression of LIMCH1 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr14:41,112,579...41,425,001
Ensembl chr14:41,114,803...41,425,191
|
|
G |
Lmcd1 |
LIM and cysteine-rich domains 1 |
decreases expression |
ISO |
Cytarabine results in decreased expression of LMCD1 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 4:145,393,153...145,452,049
Ensembl chr 4:145,393,145...145,452,046
|
|
G |
Lox |
lysyl oxidase |
decreases expression |
ISO |
Cytarabine results in decreased expression of LOX mRNA |
CTD |
PMID:21198554 |
|
NCBI chr18:45,964,544...45,977,431
Ensembl chr18:45,967,343...46,041,477
|
|
G |
Loxl4 |
lysyl oxidase-like 4 |
decreases expression |
ISO |
Cytarabine results in decreased expression of LOXL4 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 1:241,396,183...241,416,385
Ensembl chr 1:241,397,983...241,416,322
|
|
G |
Lrba |
LPS responsive beige-like anchor protein |
decreases expression |
ISO |
Cytarabine results in decreased expression of LRBA mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 2:171,623,668...172,202,576
Ensembl chr 2:171,621,507...172,202,724
|
|
G |
Lrfn5 |
leucine rich repeat and fibronectin type III domain containing 5 |
decreases expression |
ISO |
Cytarabine results in decreased expression of LRFN5 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 6:79,466,403...79,822,821
Ensembl chr 6:79,467,961...79,822,815
|
|
G |
Lrig1 |
leucine-rich repeats and immunoglobulin-like domains 1 |
increases expression |
ISO |
Cytarabine results in increased expression of LRIG1 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 4:127,130,899...127,230,956
Ensembl chr 4:127,130,898...127,231,513
|
|
G |
Lrp1b |
LDL receptor related protein 1B |
decreases expression |
ISO |
Cytarabine results in decreased expression of LRP1B mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 3:24,594,302...26,715,037
Ensembl chr 3:24,594,991...26,715,505
|
|
G |
Lrrc32 |
leucine rich repeat containing 32 |
decreases expression |
ISO |
Cytarabine results in decreased expression of LRRC32 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 1:152,785,709...152,802,997
Ensembl chr 1:152,786,511...152,798,373
|
|
G |
Lrrc41 |
leucine rich repeat containing 41 |
decreases expression |
ISO |
Cytarabine results in decreased expression of LRRC41 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 5:129,554,547...129,575,450
Ensembl chr 5:129,554,547...129,575,449
|
|
G |
Lrrn2 |
leucine rich repeat neuronal 2 |
decreases expression |
ISO |
Cytarabine results in decreased expression of LRRN2 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr13:44,321,944...44,382,454
Ensembl chr13:44,321,364...44,382,482
|
|
G |
Lrrn3 |
leucine rich repeat neuronal 3 |
increases expression |
ISO |
Cytarabine results in increased expression of LRRN3 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 6:58,489,060...58,520,322
Ensembl chr 6:58,489,010...58,520,330
|
|
G |
Lrrn4 |
leucine rich repeat neuronal 4 |
decreases expression |
ISO |
Cytarabine results in decreased expression of LRRN4 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 3:120,138,093...120,150,877
Ensembl chr 3:120,139,410...120,150,831
|
|
G |
Lum |
lumican |
decreases expression |
ISO |
Cytarabine results in decreased expression of LUM mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 7:32,358,990...32,365,794
Ensembl chr 7:32,358,614...32,365,793
|
|
G |
Ly6h |
lymphocyte antigen 6 family member H |
decreases expression |
ISO |
Cytarabine results in decreased expression of LY6H mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 7:107,258,779...107,261,270
Ensembl chr 7:107,258,779...107,261,454
|
|
G |
Ly75 |
lymphocyte antigen 75 |
increases expression |
ISO |
Cytarabine results in increased expression of LY75 mRNA |
CTD |
PMID:19194470 |
|
NCBI chr 3:44,764,702...44,852,219
Ensembl chr 3:44,765,122...44,852,374
|
|
G |
Lyl1 |
LYL1, basic helix-loop-helix family member |
decreases response to substance |
ISO |
LYL1 protein results in decreased susceptibility to Cytarabine |
CTD |
PMID:16094422 |
|
NCBI chr19:23,452,140...23,455,007
Ensembl chr19:23,452,140...23,455,007
|
|
G |
Lyn |
LYN proto-oncogene, Src family tyrosine kinase |
decreases expression |
ISO |
Cytarabine results in decreased expression of LYN mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 5:16,639,512...16,755,501
Ensembl chr 5:16,639,466...16,756,868
|
|
G |
Lyz2 |
lysozyme 2 |
increases expression |
ISO |
Cytarabine results in increased expression of LYZ mRNA |
CTD |
PMID:19194470 |
|
NCBI chr 7:52,906,810...52,912,154
Ensembl chr 7:52,906,811...52,912,106
|
|
G |
Mab21l2 |
mab-21 like 2 |
decreases expression |
ISO |
Cytarabine results in decreased expression of MAB21L2 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 2:171,946,573...171,949,655
Ensembl chr 2:171,946,573...171,949,655
|
|
G |
Magi1 |
membrane associated guanylate kinase, WW and PDZ domain containing 1 |
increases expression |
ISO |
Cytarabine results in increased expression of MAGI1 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 4:126,205,663...126,811,354
Ensembl chr 4:126,206,816...126,811,691
|
|
G |
Map2 |
microtubule-associated protein 2 |
decreases expression increases expression |
ISO |
Cytarabine results in decreased expression of MAP2 protein Cytarabine results in increased expression of MAP2 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 9:67,723,422...67,981,886
Ensembl chr 9:67,723,371...67,979,809
|
|
G |
Marchf3 |
membrane associated ring-CH-type finger 3 |
decreases expression |
ISO |
Cytarabine results in decreased expression of MARCHF3 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr18:50,237,218...50,389,343
Ensembl chr18:50,237,230...50,389,150
|
|
G |
Matn2 |
matrilin 2 |
decreases expression |
ISO |
Cytarabine results in decreased expression of MATN2 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 7:65,494,996...65,644,613
Ensembl chr 7:65,494,834...65,645,113
|
|
G |
Mbtd1 |
mbt domain containing 1 |
increases expression |
ISO |
Cytarabine results in increased expression of MBTD1 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr10:78,839,140...78,895,413
Ensembl chr10:78,839,036...78,893,720
|
|
G |
Mcl1 |
MCL1 apoptosis regulator, BCL2 family member |
decreases expression |
ISO |
Cytarabine results in decreased expression of MCL1 protein |
CTD |
PMID:16818278 |
|
NCBI chr 2:183,219,137...183,235,676
Ensembl chr 2:183,219,220...183,222,303
|
|
G |
Mcoln3 |
mucolipin TRP cation channel 3 |
decreases expression |
ISO |
Cytarabine results in decreased expression of MCOLN3 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 2:235,008,716...235,042,885
Ensembl chr 2:234,966,010...235,043,047
|
|
G |
Mdk |
midkine |
decreases expression |
ISO |
Cytarabine results in decreased expression of MDK mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 3:77,901,134...77,903,997
Ensembl chr 3:77,901,158...77,903,130
|
|
G |
Med9 |
mediator complex subunit 9 |
decreases expression |
ISO |
Cytarabine results in decreased expression of MED9 mRNA |
CTD |
PMID:19194470 |
|
NCBI chr10:44,750,667...44,765,464
Ensembl chr10:44,750,698...44,765,464
|
|
G |
Megf10 |
multiple EGF-like domains 10 |
increases expression |
ISO |
Cytarabine results in increased expression of MEGF10 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr18:50,605,231...50,755,441
Ensembl chr18:50,605,656...50,754,456
|
|
G |
Meis1 |
Meis homeobox 1 |
increases expression |
ISO |
Cytarabine results in increased expression of MEIS1 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr14:93,155,426...93,294,373
Ensembl chr14:93,155,419...93,294,265
|
|
G |
Mertk |
MER proto-oncogene, tyrosine kinase |
decreases expression |
ISO |
Cytarabine results in decreased expression of MERTK mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 3:115,939,351...116,045,141
Ensembl chr 3:115,939,351...116,046,554
|
|
G |
Mfap4 |
microfibril associated protein 4 |
decreases expression |
ISO |
Cytarabine results in decreased expression of MFAP4 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr10:46,167,158...46,170,176
Ensembl chr10:46,167,217...46,170,155
|
|
G |
Mgarp |
mitochondria-localized glutamic acid-rich protein |
decreases expression |
ISO |
Cytarabine results in decreased expression of MGARP mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 2:135,431,283...135,439,425
Ensembl chr 2:135,431,283...135,439,612
|
|
G |
Mgp |
matrix Gla protein |
decreases expression |
ISO |
Cytarabine results in decreased expression of MGP mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 4:169,766,290...169,769,612
Ensembl chr 4:169,766,279...169,769,667
|
|
G |
Mindy4 |
MINDY lysine 48 deubiquitinase 4 |
decreases expression |
ISO |
Cytarabine results in decreased expression of MINDY4 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 4:84,358,660...84,469,189
Ensembl chr 4:84,358,902...84,463,395
|
|
G |
Mmp23 |
matrix metallopeptidase 23 |
decreases expression |
ISO |
Cytarabine results in decreased expression of MMP23B mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 5:166,239,643...166,242,734
Ensembl chr 5:166,239,644...166,242,433
|
|
G |
Mpzl1 |
myelin protein zero-like 1 |
decreases expression |
ISO |
Cytarabine results in decreased expression of MPZL1 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr13:77,852,467...77,889,305
Ensembl chr13:77,852,467...77,896,616
|
|
G |
Msx1 |
msh homeobox 1 |
decreases expression |
ISO |
Cytarabine results in decreased expression of MSX1 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr14:72,961,036...72,964,970
Ensembl chr14:72,961,148...72,964,966
|
|
G |
Mt1 |
metallothionein 1 |
decreases expression |
ISO |
Cytarabine results in decreased expression of MT1A mRNA |
CTD |
PMID:21198554 |
|
NCBI chr19:10,826,032...10,827,048
Ensembl chr19:10,826,032...10,827,049 Ensembl chr17:10,826,032...10,827,049 Ensembl chr X:10,826,032...10,827,049
|
|
G |
Mt1-ps3 |
metallothionein 1, pseudogene 3 |
decreases expression |
ISO |
Cytarabine results in decreased expression of MT1E mRNA |
CTD |
PMID:21198554 |
|
NCBI chr17:74,786,652...74,787,040
Ensembl chr17:74,786,654...74,787,135
|
|
G |
Mt2A |
metallothionein 2A |
decreases expression |
ISO |
Cytarabine results in decreased expression of MT2A mRNA |
CTD |
PMID:21198554 |
|
NCBI chr19:10,832,009...10,832,783
Ensembl chr19:10,832,002...10,832,784
|
|
G |
Mthfr |
methylenetetrahydrofolate reductase |
affects response to substance |
ISO |
MTHFR protein affects the susceptibility to Cytarabine |
CTD |
PMID:18202788 |
|
NCBI chr 5:158,465,248...158,484,999
Ensembl chr 5:158,465,296...158,483,797
|
|
G |
Mtus1 |
microtubule associated scaffold protein 1 |
increases expression |
ISO |
Cytarabine results in increased expression of MTUS1 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr16:51,202,497...51,347,794
Ensembl chr16:51,253,562...51,347,793
|
|
G |
Mvb12a |
multivesicular body subunit 12A |
decreases expression |
ISO |
Cytarabine results in decreased expression of MVB12A mRNA |
CTD |
PMID:21198554 |
|
NCBI chr16:18,252,227...18,257,111
Ensembl chr16:18,252,222...18,257,539
|
|
G |
Mxd3 |
Max dimerization protein 3 |
increases expression |
ISO |
Cytarabine results in increased expression of MXD3 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr17:9,301,430...9,305,156
Ensembl chr17:9,301,399...9,305,157
|
|
G |
Mxra7 |
matrix remodeling associated 7 |
decreases expression |
ISO |
Cytarabine results in decreased expression of MXRA7 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr10:102,003,034...102,031,428
Ensembl chr10:102,003,319...102,031,409
|
|
G |
Myadm |
myeloid-associated differentiation marker |
decreases expression |
ISO |
Cytarabine results in decreased expression of MYADM mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 1:65,864,180...65,874,701
Ensembl chr 1:65,864,173...65,874,035
|
|
G |
Mydgf |
myeloid-derived growth factor |
decreases expression |
ISO |
Cytarabine results in decreased expression of MYDGF mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 9:999,659...1,008,804
Ensembl chr 9:1,000,722...1,008,822
|
|
G |
Myl4 |
myosin, light chain 4 |
decreases expression |
ISO |
Cytarabine results in decreased expression of MYL4 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr10:89,449,456...89,485,365
Ensembl chr10:89,449,443...89,485,363
|
|
G |
Myl7 |
myosin light chain 7 |
decreases expression |
ISO |
Cytarabine results in decreased expression of MYL7 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr14:80,780,684...80,783,259
Ensembl chr14:80,779,776...80,783,244
|
|
G |
Mylip |
myosin regulatory light chain interacting protein |
decreases expression |
ISO |
Cytarabine results in decreased expression of MYLIP mRNA |
CTD |
PMID:21198554 |
|
NCBI chr17:19,286,649...19,308,295
Ensembl chr17:19,286,650...19,308,295
|
|
G |
Myof |
myoferlin |
decreases expression |
ISO |
Cytarabine results in decreased expression of MYOF mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 1:235,673,666...235,822,413
Ensembl chr 1:235,673,666...235,822,334
|
|
G |
Nav2 |
neuron navigator 2 |
decreases expression |
ISO |
Cytarabine results in decreased expression of NAV2 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 1:98,957,629...99,322,339
Ensembl chr 1:98,663,759...99,322,337
|
|
G |
Ncald |
neurocalcin delta |
increases expression |
ISO |
Cytarabine results in increased expression of NCALD mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 7:68,532,671...68,964,740
Ensembl chr 7:68,534,421...68,964,496
|
|
G |
Ndc80 |
NDC80 kinetochore complex component |
increases expression |
ISO |
Cytarabine results in increased expression of NDC80 mRNA |
CTD |
PMID:19194470 |
|
NCBI chr 9:111,407,191...111,440,921
Ensembl chr 9:111,407,191...111,440,924
|
|
G |
Ndrg1 |
N-myc downstream regulated 1 |
decreases expression |
ISO |
Cytarabine results in decreased expression of NDRG1 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 7:98,684,487...98,725,869
Ensembl chr 7:98,684,487...98,725,880
|
|
G |
Ndrg2 |
NDRG family member 2 |
decreases expression |
ISO |
Cytarabine results in decreased expression of NDRG2 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr15:24,600,981...24,609,621
Ensembl chr15:24,600,982...24,609,626
|
|
G |
Nell2 |
neural EGFL like 2 |
increases expression |
ISO |
Cytarabine results in increased expression of NELL2 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 7:126,343,089...126,662,903
Ensembl chr 7:126,198,851...126,733,503
|
|
G |
Nes |
nestin |
increases expression decreases expression |
ISO |
Cytarabine results in increased expression of NES mRNA Cytarabine results in decreased expression of NES protein |
CTD |
PMID:21198554 |
|
NCBI chr 2:173,437,867...173,447,777
Ensembl chr 2:173,438,734...173,447,777
|
|
G |
Nfib |
nuclear factor I/B |
increases expression |
ISO |
Cytarabine results in increased expression of NFIB mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 5:96,759,208...96,974,001
Ensembl chr 5:96,764,653...96,975,479
|
|
G |
Nherf1 |
NHERF family PDZ scaffold protein 1 |
decreases expression |
ISO |
Cytarabine results in decreased expression of NHERF1 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr10:100,403,189...100,420,290
Ensembl chr10:100,403,069...100,420,598
|
|
G |
Niban2 |
niban apoptosis regulator 2 |
decreases expression |
ISO |
Cytarabine results in decreased expression of NIBAN2 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 3:16,174,674...16,224,293
Ensembl chr 3:16,174,659...16,224,293
|
|
G |
Nmu |
neuromedin U |
increases expression |
ISO |
Cytarabine results in increased expression of NMU mRNA |
CTD |
PMID:21198554 |
|
NCBI chr14:31,844,564...31,872,196
Ensembl chr14:31,844,728...31,872,192
|
|
G |
Nova1 |
NOVA alternative splicing regulator 1 |
increases expression |
ISO |
Cytarabine results in increased expression of NOVA1 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 6:63,780,105...63,905,567
Ensembl chr 6:63,783,489...63,906,289
|
|
G |
Nox4 |
NADPH oxidase 4 |
decreases expression |
ISO |
Cytarabine results in decreased expression of NOX4 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 1:140,900,886...141,078,844
Ensembl chr 1:140,901,097...141,077,406
|
|
G |
Nppb |
natriuretic peptide B |
increases expression |
ISO |
Cytarabine results in increased expression of NPPB mRNA; Cytarabine results in increased expression of NPPB protein |
CTD |
PMID:16151589 PMID:21198554 |
|
NCBI chr 5:158,416,813...158,418,175
Ensembl chr 5:158,416,866...158,418,168
|
|
G |
Npy |
neuropeptide Y |
decreases expression |
ISO |
Cytarabine results in decreased expression of NPY mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 4:78,881,294...78,888,495
Ensembl chr 4:78,881,264...78,888,495
|
|
G |
Nrip3 |
nuclear receptor interacting protein 3 |
decreases expression |
ISO |
Cytarabine results in decreased expression of NRIP3 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 1:163,789,738...163,815,036
Ensembl chr 1:163,789,738...163,815,600
|
|
G |
Nrp1 |
neuropilin 1 |
multiple interactions |
ISO |
[2,2-bis(4-glycidyloxyphenyl)propane co-treated with Cytarabine] results in decreased expression of NRP1 mRNA |
CTD |
PMID:23264188 |
|
NCBI chr19:56,359,455...56,514,628
Ensembl chr19:56,359,455...56,513,633
|
|
G |
Ntm |
neurotrimin |
decreases expression |
ISO |
Cytarabine results in decreased expression of NTM mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 8:27,376,582...28,366,604
Ensembl chr 8:27,377,773...28,366,595
|
|
G |
Ntng1 |
netrin G1 |
increases expression |
ISO |
Cytarabine results in increased expression of NTNG1 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 2:197,462,785...197,827,681
Ensembl chr 2:197,463,945...197,826,997
|
|
G |
Odam |
odontogenic, ameloblast associated |
decreases expression |
ISO |
Cytarabine results in decreased expression of ODAM mRNA |
CTD |
PMID:21198554 |
|
NCBI chr14:20,193,286...20,202,517
Ensembl chr14:20,193,302...20,202,517
|
|
G |
Olfml3 |
olfactomedin-like 3 |
decreases expression |
ISO |
Cytarabine results in decreased expression of OLFML3 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 2:191,244,221...191,247,050
Ensembl chr 2:191,244,221...191,247,050
|
|
G |
Olr1 |
oxidized low density lipoprotein receptor 1 |
decreases expression |
ISO |
Cytarabine results in decreased expression of OLR1 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 4:162,926,436...162,949,057
Ensembl chr 4:162,926,439...162,948,523
|
|
G |
Osbpl10 |
oxysterol binding protein-like 10 |
decreases expression |
ISO |
Cytarabine results in decreased expression of OSBPL10 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 8:114,661,050...114,918,664
Ensembl chr 8:114,660,743...114,918,625
|
|
G |
Osr1 |
odd-skipped related transcription factor 1 |
decreases expression |
ISO |
Cytarabine results in decreased expression of OSR1 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 6:32,369,561...32,380,822
Ensembl chr 6:32,373,816...32,380,817
|
|
G |
P4ha2 |
prolyl 4-hydroxylase subunit alpha 2 |
decreases expression |
ISO |
Cytarabine results in decreased expression of P4HA2 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr10:38,243,136...38,271,983
Ensembl chr10:38,243,139...38,287,314
|
|
G |
Pals2 |
protein associated with LIN7 2, MAGUK p55 family member |
decreases expression |
ISO |
Cytarabine results in decreased expression of PALS2 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 4:79,173,488...79,257,542
Ensembl chr 4:79,124,806...79,254,140
|
|
G |
Pamr1 |
peptidase domain containing associated with muscle regeneration 1 |
decreases expression |
ISO |
Cytarabine results in decreased expression of PAMR1 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 3:88,889,061...88,988,615
Ensembl chr 3:88,889,046...88,988,606
|
|
G |
Pard6a |
par-6 family cell polarity regulator alpha |
decreases expression |
ISO |
Cytarabine results in decreased expression of PARD6A mRNA |
CTD |
PMID:19194470 |
|
NCBI chr19:33,589,531...33,591,900
Ensembl chr19:33,589,542...33,591,900
|
|
G |
Parm1 |
prostate androgen-regulated mucin-like protein 1 |
decreases expression |
ISO |
Cytarabine results in decreased expression of PARM1 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr14:16,468,309...16,577,339
Ensembl chr14:16,468,459...16,577,314
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions increases degradation |
ISO |
[Cytarabine co-treated with TNFSF10 protein] results in increased cleavage of PARP1 protein; BCL2 protein inhibits the reaction [Cytarabine results in increased degradation of PARP1 protein]; BCL2L1 protein inhibits the reaction [Cytarabine results in increased degradation of PARP1 protein] |
CTD |
PMID:8840993 PMID:12780785 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Pax6 |
paired box 6 |
increases expression decreases expression |
ISO |
Cytarabine results in increased expression of PAX6 mRNA Cytarabine results in decreased expression of PAX6 protein |
CTD |
PMID:21198554 |
|
NCBI chr 3:92,128,772...92,157,022
Ensembl chr 3:92,135,637...92,157,014
|
|
G |
Pcdh20 |
protocadherin 20 |
decreases expression |
ISO |
Cytarabine results in decreased expression of PCDH20 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr15:64,425,534...64,431,790
Ensembl chr15:64,425,534...64,431,790
|
|
G |
Pcdh7 |
protocadherin 7 |
decreases expression |
ISO |
Cytarabine results in decreased expression of PCDH7 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr14:52,471,801...52,901,696
Ensembl chr14:52,475,610...52,902,051 Ensembl chr14:52,475,610...52,902,051
|
|
G |
Pced1b |
PC-esterase domain containing 1B |
decreases expression |
ISO |
Cytarabine results in decreased expression of PCED1B mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 7:128,394,388...128,528,231
Ensembl chr 7:128,391,319...128,528,231
|
|
G |
Pcsk5 |
proprotein convertase subtilisin/kexin type 5 |
decreases expression |
ISO |
Cytarabine results in decreased expression of PCSK5 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 1:214,837,847...215,267,626
Ensembl chr 1:214,837,927...215,267,600
|
|
G |
Pde1a |
phosphodiesterase 1A |
increases expression |
ISO |
Cytarabine results in increased expression of PDE1A mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 3:64,745,140...65,025,178
Ensembl chr 3:64,747,269...65,024,874
|
|
G |
Pde1b |
phosphodiesterase 1B |
increases expression |
ISO |
Cytarabine results in increased expression of PDE1B mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 7:134,627,378...134,654,581
Ensembl chr 7:134,627,322...134,654,580
|
|
G |
Pde4b |
phosphodiesterase 4B |
increases expression |
ISO |
Cytarabine results in increased expression of PDE4B mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 5:116,799,819...117,369,155
Ensembl chr 5:116,799,971...117,367,696
|
|
G |
Pde6d |
phosphodiesterase 6D |
decreases expression |
ISO |
Cytarabine results in decreased expression of PDE6D mRNA |
CTD |
PMID:19194470 |
|
NCBI chr 9:87,192,989...87,237,979
Ensembl chr 9:87,192,983...87,237,969
|
|
G |
Pdgfrb |
platelet derived growth factor receptor beta |
decreases expression |
ISO |
Cytarabine results in decreased expression of PDGFRB mRNA |
CTD |
PMID:21198554 |
|
NCBI chr18:54,499,962...54,538,840
Ensembl chr18:54,499,964...54,538,843
|
|
G |
Pdlim3 |
PDZ and LIM domain 3 |
increases expression |
ISO |
Cytarabine results in increased expression of PDLIM3 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr16:46,352,460...46,383,680
Ensembl chr16:46,352,467...46,383,657
|
|
G |
Pdlim4 |
PDZ and LIM domain 4 |
multiple interactions |
ISO |
Cytarabine inhibits the reaction [decitabine results in increased expression of PDLIM4 mRNA] |
CTD |
PMID:17634552 |
|
NCBI chr10:38,198,686...38,212,935
Ensembl chr10:38,198,689...38,212,938
|
|
G |
Pdpn |
podoplanin |
decreases expression |
ISO |
Cytarabine results in decreased expression of PDPN mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 5:155,601,691...155,635,656
Ensembl chr 5:155,601,691...155,635,656
|
|
G |
Peli1 |
pellino E3 ubiquitin protein ligase 1 |
increases expression |
ISO |
Cytarabine results in increased expression of PELI1 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr14:95,254,274...95,309,168
Ensembl chr14:95,254,589...95,308,285 Ensembl chr 1:95,254,589...95,308,285
|
|
G |
Pfkp |
phosphofructokinase, platelet |
decreases expression |
ISO |
Cytarabine results in decreased expression of PFKP mRNA |
CTD |
PMID:21198554 |
|
NCBI chr17:63,729,743...63,794,026
Ensembl chr17:63,729,780...63,794,018
|
|
G |
Pgm5 |
phosphoglucomutase 5 |
decreases expression |
ISO |
Cytarabine results in decreased expression of PGM5 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 1:222,325,638...222,513,434
Ensembl chr 1:222,325,643...222,513,437
|
|
G |
Phactr2 |
phosphatase and actin regulator 2 |
decreases expression |
ISO |
Cytarabine results in decreased expression of PHACTR2 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 1:7,591,254...7,860,431
Ensembl chr 1:7,597,927...7,860,289
|
|
G |
Phyhipl |
phytanoyl-CoA 2-hydroxylase interacting protein-like |
increases expression |
ISO |
Cytarabine results in increased expression of PHYHIPL mRNA |
CTD |
PMID:21198554 |
|
NCBI chr20:18,024,744...18,065,822
Ensembl chr20:18,024,666...18,065,478
|
|
G |
Pigh |
phosphatidylinositol glycan anchor biosynthesis, class H |
decreases expression |
ISO |
Cytarabine results in decreased expression of PIGH mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 6:97,874,903...97,897,188
Ensembl chr 6:97,882,903...97,897,142
|
|
G |
Pitx1 |
paired-like homeodomain 1 |
decreases expression |
ISO |
Cytarabine results in decreased expression of PITX1 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr17:8,794,134...8,800,292
Ensembl chr17:8,794,134...8,800,291
|
|
G |
Pitx2 |
paired-like homeodomain 2 |
decreases expression |
ISO |
Cytarabine results in decreased expression of PITX2 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 2:217,717,738...217,737,293
Ensembl chr 2:217,717,693...217,737,293
|
|
G |
Pkia |
cAMP-dependent protein kinase inhibitor alpha |
decreases expression |
ISO |
Cytarabine results in decreased expression of PKIA mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 2:94,398,869...94,473,638
Ensembl chr 2:94,398,869...94,414,282
|
|
G |
Pkp2 |
plakophilin 2 |
decreases expression |
ISO |
Cytarabine results in decreased expression of PKP2 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr11:84,661,783...84,727,730
Ensembl chr11:84,661,783...84,727,730
|
|
G |
Plac9 |
placenta associated 9 |
decreases expression |
ISO |
Cytarabine results in decreased expression of PLAC9 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr16:1,459,450...1,474,275
Ensembl chr16:1,459,456...1,474,399
|
|
G |
Plat |
plasminogen activator, tissue type |
decreases expression |
ISO |
Cytarabine results in decreased expression of PLAT mRNA |
CTD |
PMID:21198554 |
|
NCBI chr16:69,240,582...69,265,177
Ensembl chr16:69,240,585...69,268,223
|
|
G |
Plcb2 |
phospholipase C, beta 2 |
affects localization multiple interactions |
ISO |
Cytarabine affects the localization of PLCB2 protein edelfosine inhibits the reaction [Cytarabine affects the localization of PLCB2 protein] |
CTD |
PMID:9295281 |
|
NCBI chr 3:105,683,676...105,704,384
Ensembl chr 3:105,684,815...105,704,302
|
|
G |
Plch1 |
phospholipase C, eta 1 |
increases expression |
ISO |
Cytarabine results in increased expression of PLCH1 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 2:148,148,908...148,363,616
Ensembl chr 2:148,148,921...148,364,097
|
|
G |
Pld3 |
phospholipase D family, member 3 |
decreases expression |
ISO |
Cytarabine results in decreased expression of PLD3 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 1:82,821,863...82,844,280
Ensembl chr 1:82,821,875...82,844,072
|
|
G |
Plekhg3 |
pleckstrin homology and RhoGEF domain containing G3 |
decreases expression |
ISO |
Cytarabine results in decreased expression of PLEKHG3 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 6:95,265,756...95,308,952
Ensembl chr 6:95,266,058...95,310,359
|
|
G |
Plg |
plasminogen |
affects localization |
ISO |
Cytarabine affects the localization of PLG protein |
CTD |
PMID:12165291 |
|
NCBI chr 1:48,325,186...48,367,643
Ensembl chr 1:48,325,185...48,367,786
|
|
G |
Plin3 |
perilipin 3 |
decreases expression |
ISO |
Cytarabine results in decreased expression of PLIN3 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 9:1,111,178...1,123,057
Ensembl chr 9:1,102,366...1,123,147
|
|
G |
Pllp |
plasmolipin |
decreases expression |
ISO |
Cytarabine results in decreased expression of PLLP mRNA |
CTD |
PMID:21198554 |
|
NCBI chr19:10,315,104...10,335,892
Ensembl chr19:10,315,104...10,335,892
|
|
G |
Plod1 |
procollagen-lysine, 2-oxoglutarate 5-dioxygenase 1 |
decreases expression |
ISO |
Cytarabine results in decreased expression of PLOD1 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 5:158,340,674...158,367,581
Ensembl chr 5:158,340,490...158,367,620
|
|
G |
Plp1 |
proteolipid protein 1 |
increases expression |
ISO |
Cytarabine results in increased expression of PLP1 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr X:100,184,039...100,201,035
Ensembl chr X:100,185,767...100,201,032
|
|
G |
Pltp |
phospholipid transfer protein |
decreases expression |
ISO |
Cytarabine results in decreased expression of PLTP mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 3:153,574,825...153,592,647
Ensembl chr 3:153,574,825...153,592,647
|
|
G |
Pmel |
premelanosome protein |
increases expression |
ISO |
Cytarabine results in increased expression of PMEL mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 7:1,138,202...1,148,735
Ensembl chr 7:1,138,586...1,148,746
|
|
G |
Pmp22 |
peripheral myelin protein 22 |
decreases expression |
ISO |
Cytarabine results in decreased expression of PMP22 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr10:47,795,709...47,825,715
Ensembl chr10:47,795,709...47,825,714
|
|
G |
Podxl |
podocalyxin-like |
decreases expression |
ISO |
Cytarabine results in decreased expression of PODXL mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 4:60,135,124...60,181,829
Ensembl chr 4:60,135,109...60,181,899
|
|
G |
Podxl2 |
podocalyxin-like 2 |
increases expression |
ISO |
Cytarabine results in increased expression of PODXL2 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 4:121,306,224...121,338,070
Ensembl chr 4:121,306,224...121,338,112
|
|
G |
Postn |
periostin |
decreases expression |
ISO |
Cytarabine results in decreased expression of POSTN mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 2:138,527,714...138,559,098
Ensembl chr 2:138,527,696...138,559,099
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
multiple interactions increases expression |
ISO |
2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [Cytarabine results in increased expression of PPARG mRNA] |
CTD |
PMID:23264188 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Ppic |
peptidylprolyl isomerase C |
decreases expression |
ISO |
Cytarabine results in decreased expression of PPIC mRNA |
CTD |
PMID:21198554 |
|
NCBI chr18:46,842,410...46,855,016
Ensembl chr18:46,842,409...46,855,017
|
|
G |
Ppm1m |
protein phosphatase, Mg2+/Mn2+ dependent, 1M |
decreases expression |
ISO |
Cytarabine results in decreased expression of PPM1M mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 8:106,836,221...106,843,472
Ensembl chr 8:106,837,037...106,842,057
|
|
G |
Ppt2 |
palmitoyl-protein thioesterase 2 |
decreases expression |
ISO |
Cytarabine results in decreased expression of PPT2 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr20:4,112,520...4,132,774
Ensembl chr20:4,122,463...4,132,774
|
|
G |
Prc1 |
protein regulator of cytokinesis 1 |
decreases expression |
ISO |
Cytarabine results in decreased expression of PRC1 mRNA |
CTD |
PMID:17374387 |
|
NCBI chr 1:134,250,086...134,271,765
Ensembl chr 1:134,250,081...134,271,765
|
|
G |
Prdm8 |
PR/SET domain 8 |
increases expression |
ISO |
Cytarabine results in increased expression of PRDM8 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr14:11,403,202...11,424,059
Ensembl chr14:11,404,407...11,410,993
|
|
G |
Prickle1 |
prickle planar cell polarity protein 1 |
decreases expression |
ISO |
Cytarabine results in decreased expression of PRICKLE1 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 7:124,639,142...124,735,027
Ensembl chr 7:124,639,142...124,658,113
|
|
G |
Prkcz |
protein kinase C, zeta |
decreases response to substance |
ISO |
PRKCZ protein results in decreased susceptibility to Cytarabine |
CTD |
PMID:21863889 |
|
NCBI chr 5:165,817,786...165,930,386
Ensembl chr 5:165,819,466...165,930,367
|
|
G |
Prl |
prolactin |
increases expression |
ISO |
Cytarabine results in increased expression of PRL protein |
CTD |
PMID:8312290 |
|
NCBI chr17:37,859,999...37,870,062
Ensembl chr17:37,860,007...37,870,062
|
|
G |
Prnp |
prion protein |
decreases expression |
ISO |
Cytarabine results in decreased expression of PRNP mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 3:119,186,073...119,201,513
Ensembl chr 3:119,177,485...119,203,937
|
|
G |
Prph |
peripherin |
decreases expression |
ISO |
Cytarabine results in decreased expression of PRPH mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 7:130,218,149...130,222,136
Ensembl chr 7:130,218,357...130,222,136
|
|
G |
Prrc2c |
proline-rich coiled-coil 2C |
decreases expression |
ISO |
Cytarabine results in decreased expression of PRRC2C mRNA |
CTD |
PMID:19194470 |
|
NCBI chr13:75,003,995...75,073,701
Ensembl chr13:75,004,010...75,073,643
|
|
G |
Prss35 |
serine protease 35 |
decreases expression |
ISO |
Cytarabine results in decreased expression of PRSS35 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 8:87,714,449...87,731,009
Ensembl chr 8:87,714,966...87,731,009
|
|
G |
Psd3 |
pleckstrin and Sec7 domain containing 3 |
increases expression |
ISO |
Cytarabine results in increased expression of PSD3 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr16:21,465,643...22,035,846
Ensembl chr16:21,465,639...22,034,547
|
|
G |
Psrc1 |
proline and serine rich coiled-coil 1 |
decreases expression |
ISO |
Cytarabine results in decreased expression of PSRC1 mRNA |
CTD |
PMID:17374387 |
|
NCBI chr 2:196,022,361...196,026,874
Ensembl chr 2:196,022,361...196,026,874
|
|
G |
Pstpip2 |
proline-serine-threonine phosphatase-interacting protein 2 |
decreases expression |
ISO |
Cytarabine results in decreased expression of PSTPIP2 mRNA |
CTD |
PMID:19194470 |
|
NCBI chr18:71,310,387...71,396,752
Ensembl chr18:71,311,020...71,395,709
|
|
G |
Pten |
phosphatase and tensin homolog |
increases response to substance |
ISO |
PTEN protein results in increased susceptibility to Cytarabine |
CTD |
PMID:22185283 |
|
NCBI chr 1:230,630,443...230,697,070
Ensembl chr 1:230,630,338...230,696,838
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
PTGS2 mutant form affects the reaction [VEGFC protein results in decreased susceptibility to Cytarabine] PTGS2 mutant form inhibits the reaction [VEGFC protein results in decreased susceptibility to Cytarabine] |
CTD |
PMID:24184161 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Pth1r |
parathyroid hormone 1 receptor |
decreases expression |
ISO |
Cytarabine results in decreased expression of PTH1R mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 8:110,693,910...110,725,458
Ensembl chr 8:110,697,485...110,719,729
|
|
G |
Ptprz1 |
protein tyrosine phosphatase, receptor type Z1 |
increases expression |
ISO |
Cytarabine results in increased expression of PTPRZ1 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 4:51,397,316...51,595,220
Ensembl chr 4:51,397,601...51,595,218
|
|
G |
Qprt |
quinolinate phosphoribosyltransferase |
decreases expression |
ISO |
Cytarabine results in decreased expression of QPRT mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 1:181,718,189...181,733,486
Ensembl chr 1:181,718,190...181,733,486
|
|
G |
Rab37 |
RAB37, member RAS oncogene family |
decreases expression |
ISO |
Cytarabine results in decreased expression of RAB37 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr10:100,334,639...100,401,974
Ensembl chr10:100,334,216...100,401,474
|
|
G |
Rab5b |
RAB5B, member RAS oncogene family |
increases expression |
ISO |
Cytarabine results in increased expression of RAB5B mRNA |
CTD |
PMID:19194470 |
|
NCBI chr 7:1,109,449...1,128,348
Ensembl chr 7:1,109,454...1,128,268
|
|
G |
Rabggtb |
Rab geranylgeranyltransferase subunit beta |
decreases expression |
ISO |
Cytarabine results in decreased expression of RABGGTB mRNA |
CTD |
PMID:19194470 |
|
NCBI chr 2:242,844,758...242,850,951
Ensembl chr 2:242,844,762...242,851,050
|
|
G |
Rad23a |
RAD23 homolog A, nucleotide excision repair protein |
decreases expression |
ISO |
Cytarabine results in decreased expression of RAD23A mRNA |
CTD |
PMID:19194470 |
|
NCBI chr19:23,313,563...23,320,702
Ensembl chr19:23,314,797...23,320,695
|
|
G |
Rad51 |
RAD51 recombinase |
increases expression |
ISO |
Cytarabine results in increased expression of RAD51 mRNA |
CTD |
PMID:19194470 |
|
NCBI chr 3:106,099,753...106,125,038
Ensembl chr 3:106,100,381...106,125,035
|
|
G |
Ralgdsl1 |
ral guanine nucleotide dissociation stimulator like 1 |
decreases expression |
ISO |
Cytarabine results in decreased expression of RGL1 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr13:64,634,489...64,904,170
Ensembl chr13:64,635,246...64,904,191
|
|
G |
Ramp1 |
receptor activity modifying protein 1 |
decreases expression |
ISO |
Cytarabine results in decreased expression of RAMP1 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 9:91,765,481...91,816,152
Ensembl chr 9:91,781,285...91,816,151
|
|
G |
Rassf2 |
Ras association domain family member 2 |
increases expression |
ISO |
Cytarabine results in increased expression of RASSF2 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 3:119,244,288...119,280,462
Ensembl chr 3:119,245,821...119,280,431
|
|
G |
Rbm34 |
RNA binding motif protein 34 |
decreases expression |
ISO |
Cytarabine results in decreased expression of RBM34 mRNA |
CTD |
PMID:19194470 |
|
NCBI chr19:54,936,516...54,956,810
Ensembl chr19:54,936,531...54,956,715
|
|
G |
Recql5 |
RecQ like helicase 5 |
decreases expression |
ISO |
Cytarabine results in decreased expression of RECQL5 mRNA |
CTD |
PMID:19194470 |
|
NCBI chr10:101,126,544...101,165,739
Ensembl chr10:101,126,547...101,165,652
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions decreases phosphorylation decreases activity |
ISO |
calyculin A inhibits the reaction [Cytarabine results in decreased activity of RELA protein] Cytarabine results in decreased phosphorylation of RELA protein |
CTD |
PMID:12853972 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Reln |
reelin |
decreases expression |
ISO |
Cytarabine results in decreased expression of RELN mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 4:12,736,177...13,162,956
Ensembl chr 4:12,736,130...13,162,211
|
|
G |
Rerg |
RAS-like, estrogen-regulated, growth-inhibitor |
decreases expression |
ISO |
Cytarabine results in decreased expression of RERG mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 4:169,981,634...170,089,777
Ensembl chr 4:169,982,279...170,089,715
|
|
G |
Rexo4 |
REX4 homolog, 3'-5' exonuclease |
decreases expression |
ISO |
Cytarabine results in decreased expression of REXO4 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 3:10,280,654...10,291,003
Ensembl chr 3:10,280,654...10,290,996
|
|
G |
Rgmb |
repulsive guidance molecule BMP co-receptor b |
increases expression |
ISO |
Cytarabine results in increased expression of RGMB mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 1:56,766,598...56,792,396
Ensembl chr 1:56,767,850...56,792,425
|
|
G |
Rgs1 |
regulator of G-protein signaling 1 |
decreases expression |
ISO |
Cytarabine results in decreased expression of RGS1 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr13:56,018,546...56,022,889
Ensembl chr13:56,018,554...56,022,984
|
|
G |
Rgs13 |
regulator of G-protein signaling 13 |
decreases expression |
ISO |
Cytarabine results in decreased expression of RGS13 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr13:55,922,290...55,955,753
Ensembl chr13:55,922,395...55,955,648
|
|
G |
Rgs20 |
regulator of G-protein signaling 20 |
increases expression |
ISO |
Cytarabine results in increased expression of RGS20 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 5:14,484,436...14,614,317
Ensembl chr 5:14,534,775...14,614,084
|
|
G |
Rgs4 |
regulator of G-protein signaling 4 |
decreases expression |
ISO |
Cytarabine results in decreased expression of RGS4 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr13:81,936,775...81,943,103
Ensembl chr13:81,936,775...81,943,068
|
|
G |
Rhoc |
ras homolog family member C |
decreases expression |
ISO |
Cytarabine results in decreased expression of RHOC mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 2:192,287,065...192,293,292
Ensembl chr 2:192,287,130...192,295,306
|
|
G |
Rhpn2 |
rhophilin, Rho GTPase binding protein 2 |
decreases expression |
ISO |
Cytarabine results in decreased expression of RHPN2 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 1:87,991,143...88,051,895
Ensembl chr 1:87,991,144...88,051,902
|
|
G |
Rnase2 |
ribonuclease A family member 2 |
increases expression |
ISO |
Cytarabine results in increased expression of RNASE2 mRNA |
CTD |
PMID:19194470 |
|
NCBI chr15:24,449,618...24,450,427
Ensembl chr15:24,449,611...24,450,479
|
|
G |
Robo3 |
roundabout guidance receptor 3 |
increases expression |
ISO |
Cytarabine results in increased expression of ROBO3 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 8:37,133,542...37,151,674
Ensembl chr 8:37,133,916...37,151,315
|
|
G |
Rpp25 |
ribonuclease P and MRP subunit p25 |
decreases expression |
ISO |
Cytarabine results in decreased expression of RPP25 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 8:57,907,352...57,908,732
Ensembl chr 8:57,907,352...57,908,732
|
|
G |
Rprml |
reprimo-like |
increases expression |
ISO |
Cytarabine results in increased expression of RPRML mRNA |
CTD |
PMID:21198554 |
|
NCBI chr10:88,560,248...88,561,252
Ensembl chr10:88,560,248...88,561,252
|
|
G |
Rras |
RAS related |
decreases expression |
ISO |
Cytarabine results in decreased expression of RRAS mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 1:95,500,582...95,504,362
Ensembl chr 1:95,500,566...95,504,357
|
|
G |
Rrm2 |
ribonucleotide reductase regulatory subunit M2 |
increases expression |
ISO |
Cytarabine results in increased expression of RRM2 mRNA |
CTD |
PMID:19194470 |
|
NCBI chr 6:41,339,858...41,346,774
Ensembl chr 6:41,340,557...41,346,773
|
|
G |
Rspo2 |
R-spondin 2 |
decreases expression |
ISO |
Cytarabine results in decreased expression of RSPO2 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 7:74,096,378...74,239,398
Ensembl chr 7:74,103,090...74,238,933
|
|
G |
Rsrp1 |
arginine and serine rich protein 1 |
decreases expression |
ISO |
Cytarabine results in decreased expression of RSRP1 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 5:147,147,774...147,151,523
Ensembl chr 5:147,147,784...147,151,523
|
|
G |
Rtn1 |
reticulon 1 |
increases expression |
ISO |
Cytarabine results in increased expression of RTN1 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 6:90,763,212...90,983,436
Ensembl chr 6:90,763,216...90,983,436
|
|
G |
Rwdd1 |
RWD domain containing 1 |
increases expression |
ISO |
Cytarabine results in increased expression of RWDD1 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr20:25,949,723...25,967,147
Ensembl chr20:25,941,966...25,967,193
|
|
G |
S100a10 |
S100 calcium binding protein A10 |
decreases expression |
ISO |
Cytarabine results in decreased expression of S100A10 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 2:179,221,012...179,229,659
Ensembl chr 2:179,220,887...179,229,661
|
|
G |
S100a4 |
S100 calcium-binding protein A4 |
decreases expression |
ISO |
Cytarabine results in decreased expression of S100A4 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 2:176,090,951...176,093,258
Ensembl chr 2:176,091,804...176,093,254
|
|
G |
Saraf |
store-operated calcium entry-associated regulatory factor |
decreases expression |
ISO |
Cytarabine results in decreased expression of SARAF mRNA |
CTD |
PMID:21198554 |
|
NCBI chr16:58,017,231...58,035,481
Ensembl chr16:58,017,231...58,035,545
|
|
G |
Sbspon |
somatomedin B and thrombospondin, type 1 domain containing |
decreases expression |
ISO |
Cytarabine results in decreased expression of SBSPON mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 5:3,402,763...3,433,338
Ensembl chr 5:3,402,648...3,435,420
|
|
G |
Scamp5 |
secretory carrier membrane protein 5 |
increases expression |
ISO |
Cytarabine results in increased expression of SCAMP5 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 8:57,845,831...57,884,516
Ensembl chr 8:57,846,659...57,872,027
|
|
G |
Scyl1 |
SCY1 like pseudokinase 1 |
decreases expression |
ISO |
Cytarabine results in decreased expression of SCYL1 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 1:203,045,776...203,059,550
Ensembl chr 1:203,045,741...203,059,533
|
|
G |
Sdc4 |
syndecan 4 |
decreases expression |
ISO |
Cytarabine results in decreased expression of SDC4 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 3:153,154,888...153,173,576
Ensembl chr 3:153,154,896...153,173,580
|
|
G |
Sec14l1 |
SEC14-like lipid binding 1 |
decreases expression |
ISO |
Cytarabine results in decreased expression of SEC14L1 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr10:102,319,920...102,367,070
Ensembl chr10:102,319,920...102,367,068
|
|
G |
Selenom |
selenoprotein M |
decreases expression |
ISO |
Cytarabine results in decreased expression of SELENOM mRNA |
CTD |
PMID:21198554 |
|
NCBI chr14:78,395,826...78,398,429
Ensembl chr14:78,395,826...78,398,429
|
|
G |
Sema5b |
semaphorin 5B |
increases expression |
ISO |
Cytarabine results in increased expression of SEMA5B mRNA |
CTD |
PMID:21198554 |
|
NCBI chr11:65,102,532...65,225,456
Ensembl chr11:65,102,031...65,225,311
|
|
G |
Serpina1 |
serpin family A member 1 |
increases expression |
ISO |
Cytarabine results in increased expression of SERPINA1 mRNA |
CTD |
PMID:19194470 |
|
NCBI chr 6:122,866,314...122,888,339
Ensembl chr 6:122,866,312...122,888,339
|
|
G |
Serpinb6a |
serpin family B member 6A |
decreases expression |
ISO |
Cytarabine results in decreased expression of SERPINB6 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr17:30,871,468...30,989,703
Ensembl chr17:30,871,468...31,014,427
|
|
G |
Serpinb9 |
serpin family B member 9 |
decreases expression |
ISO |
Cytarabine results in decreased expression of SERPINB9 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr17:31,420,118...31,443,237
Ensembl chr17:31,420,125...31,443,230
|
|
G |
Serpinh1 |
serpin family H member 1 |
decreases expression |
ISO |
Cytarabine results in decreased expression of SERPINH1 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 1:153,643,500...153,650,853
Ensembl chr 1:153,643,510...153,650,801
|
|
G |
Sertad1 |
SERTA domain containing 1 |
decreases expression |
ISO |
Cytarabine results in decreased expression of SERTAD1 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 1:82,775,692...82,778,961
Ensembl chr 1:82,775,252...82,779,091
|
|
G |
Sesn3 |
sestrin 3 |
decreases expression |
ISO |
Cytarabine results in decreased expression of SESN3 mRNA |
CTD |
PMID:33770205 |
|
NCBI chr 8:11,133,822...11,189,436
Ensembl chr 8:11,133,678...11,185,842
|
|
G |
Sfn |
stratifin |
decreases response to substance |
ISO |
SFN protein results in decreased susceptibility to Cytarabine |
CTD |
PMID:25189999 |
|
NCBI chr 5:145,826,722...145,827,994
Ensembl chr 5:145,826,201...145,831,314
|
|
G |
Sfrp1 |
secreted frizzled-related protein 1 |
increases expression |
ISO |
Cytarabine results in increased expression of SFRP1 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr16:68,575,763...68,614,180
Ensembl chr16:68,575,763...68,614,286
|
|
G |
Sfrp2 |
secreted frizzled-related protein 2 |
increases expression |
ISO |
Cytarabine results in increased expression of SFRP2 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 2:169,089,517...169,097,064
Ensembl chr 2:169,089,517...169,097,063
|
|
G |
Sgip1 |
SH3GL interacting endocytic adaptor 1 |
increases expression |
ISO |
Cytarabine results in increased expression of SGIP1 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 5:117,536,752...117,734,593
Ensembl chr 5:117,537,746...117,734,575
|
|
G |
Sh3rf2 |
SH3 domain containing ring finger 2 |
decreases expression |
ISO |
Cytarabine results in decreased expression of SH3RF2 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr18:34,045,715...34,148,342
Ensembl chr18:34,046,879...34,146,856
|
|
G |
Sipa1l2 |
signal-induced proliferation-associated 1 like 2 |
decreases expression |
ISO |
Cytarabine results in decreased expression of SIPA1L2 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr19:53,389,792...53,540,466
Ensembl chr19:53,389,805...53,540,428
|
|
G |
Sla |
src-like adaptor |
increases expression |
ISO |
Cytarabine results in increased expression of SLA mRNA |
CTD |
PMID:19194470 |
|
NCBI chr 7:98,534,431...98,584,810
Ensembl chr 7:98,535,368...98,584,648
|
|
G |
Slc12a6 |
solute carrier family 12, member 6 |
decreases expression |
ISO |
Cytarabine results in decreased expression of SLC12A6 mRNA |
CTD |
PMID:33770205 |
|
NCBI chr 3:99,071,577...99,170,266
Ensembl chr 3:99,071,391...99,170,258
|
|
G |
Slc16a3 |
solute carrier family 16 member 3 |
decreases expression |
ISO |
Cytarabine results in decreased expression of SLC16A3 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr10:106,212,679...106,222,564
Ensembl chr10:106,212,778...106,222,562
|
|
G |
Slc16a9 |
solute carrier family 16, member 9 |
increases expression |
ISO |
Cytarabine results in increased expression of SLC16A9 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr20:18,335,862...18,377,125
Ensembl chr20:18,335,862...18,377,022
|
|
G |
Slc17a6 |
solute carrier family 17 member 6 |
increases expression |
ISO |
Cytarabine results in increased expression of SLC17A6 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 1:101,212,489...101,252,543
Ensembl chr 1:101,212,489...101,252,542
|
|
G |
Slc28a1 |
solute carrier family 28 member 1 |
multiple interactions |
ISO EXP |
Cytarabine inhibits the reaction [SLC28A1 protein results in increased transport of Uridine] Cytarabine inhibits the reaction [SLC28A1 protein results in increased uptake of Uridine] |
CTD |
PMID:8713072 PMID:10772724 |
|
NCBI chr 1:135,079,375...135,122,791
Ensembl chr 1:135,081,385...135,122,464
|
|
G |
Slc29a1 |
solute carrier family 29 member 1 |
decreases response to substance |
ISO |
SLC29A1 gene polymorphism results in decreased susceptibility to Cytarabine |
CTD |
PMID:18381442 |
|
NCBI chr 9:15,399,661...15,414,203
Ensembl chr 9:15,399,612...15,414,203
|
|
G |
Slc2a1 |
solute carrier family 2 member 1 |
decreases expression |
ISO |
Cytarabine results in decreased expression of SLC2A1 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 5:132,717,196...132,745,416
Ensembl chr 5:132,717,196...132,745,416
|
|
G |
Slc39a2 |
solute carrier family 39 member 2 |
decreases expression |
ISO |
Cytarabine results in decreased expression of SLC39A2 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr15:24,590,738...24,592,850
Ensembl chr15:24,590,738...24,592,850
|
|
G |
Slc40a1 |
solute carrier family 40 member 1 |
decreases expression |
ISO |
Cytarabine results in decreased expression of SLC40A1 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 9:48,033,526...48,053,876
Ensembl chr 9:48,033,526...48,051,481
|
|
G |
Slc43a3 |
solute carrier family 43, member 3 |
increases expression |
ISO |
Cytarabine results in increased expression of SLC43A3 mRNA |
CTD |
PMID:19194470 |
|
NCBI chr 3:70,008,160...70,030,324
Ensembl chr 3:70,009,313...70,029,749
|
|
G |
Slc47a1 |
solute carrier family 47 member 1 |
decreases expression |
ISO |
Cytarabine results in decreased expression of SLC47A1 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr10:46,034,115...46,088,617
Ensembl chr10:46,034,122...46,087,637
|
|
G |
Slc4a8 |
solute carrier family 4 member 8 |
decreases expression |
ISO |
Cytarabine results in decreased expression of SLC4A8 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 7:131,861,284...131,939,295
Ensembl chr 7:131,864,102...131,931,051
|
|
G |
Slc5a12 |
solute carrier family 5 member 12 |
decreases expression |
ISO |
Cytarabine results in decreased expression of SLC5A12 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 3:97,179,326...97,228,405
Ensembl chr 3:97,179,326...97,228,405
|
|
G |
Slc7a2 |
solute carrier family 7 member 2 |
decreases expression |
ISO |
Cytarabine results in decreased expression of SLC7A2 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr16:51,417,478...51,470,784
Ensembl chr16:51,417,493...51,470,784
|
|
G |
Slc7a7 |
solute carrier family 7 member 7 |
decreases expression |
ISO |
Cytarabine results in decreased expression of SLC7A7 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr15:27,822,088...27,873,121
Ensembl chr15:27,822,091...27,865,648
|
|
G |
Slfn9 |
schlafen family member 9 |
increases expression |
ISO |
Cytarabine results in increased expression of SLFN11 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr10:67,909,105...67,955,912
Ensembl chr10:67,909,106...67,925,383
|
|
G |
Slit2 |
slit guidance ligand 2 |
decreases expression |
ISO |
Cytarabine results in decreased expression of SLIT2 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr14:62,616,337...62,955,934
Ensembl chr14:62,617,067...62,955,948
|
|
G |
Slitrk3 |
SLIT and NTRK-like family, member 3 |
decreases expression |
ISO |
Cytarabine results in decreased expression of SLITRK3 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 2:157,680,067...157,697,404
Ensembl chr 2:157,687,535...157,696,709
|
|
G |
Slitrk5 |
SLIT and NTRK-like family, member 5 |
decreases expression |
ISO |
Cytarabine results in decreased expression of SLITRK5 mRNA |
CTD |
PMID:19194470 |
|
NCBI chr15:88,848,123...88,858,809
Ensembl chr15:88,847,535...88,856,836
|
|
G |
Sln |
sarcolipin |
decreases expression |
ISO |
Cytarabine results in decreased expression of SLN mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 8:54,221,389...54,248,110
Ensembl chr 8:54,243,542...54,247,791
|
|
G |
Smad6 |
SMAD family member 6 |
decreases expression |
ISO |
Cytarabine results in decreased expression of SMAD6 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 8:64,450,114...64,519,673
Ensembl chr 8:64,450,114...64,519,763
|
|
G |
Smoc2 |
SPARC related modular calcium binding 2 |
decreases expression |
ISO |
Cytarabine results in decreased expression of SMOC2 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 1:55,262,472...55,391,804
Ensembl chr 1:55,262,530...55,391,693
|
|
G |
Smpdl3a |
sphingomyelin phosphodiesterase, acid-like 3A |
decreases expression |
ISO |
Cytarabine results in decreased expression of SMPDL3A mRNA |
CTD |
PMID:21198554 |
|
NCBI chr20:37,132,592...37,155,567
Ensembl chr20:37,132,592...37,155,567
|
|
G |
Snai2 |
snail family transcriptional repressor 2 |
decreases expression |
ISO |
Cytarabine results in decreased expression of SNAI2 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr11:86,182,788...86,186,203
Ensembl chr11:86,181,909...86,186,200
|
|
G |
Snap91 |
synaptosome associated protein 91 |
increases expression |
ISO |
Cytarabine results in increased expression of SNAP91 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 8:87,738,056...87,852,690
Ensembl chr 8:87,738,824...87,852,367
|
|
G |
Snca |
synuclein alpha |
multiple interactions |
ISO |
Cytarabine promotes the reaction [SNCA protein mutant form results in increased susceptibility to ferrous chloride]; Cytarabine promotes the reaction [SNCA protein mutant form results in increased susceptibility to Iron] |
CTD |
PMID:14535945 |
|
NCBI chr 4:89,696,420...89,797,240
Ensembl chr 4:89,696,420...89,796,262
|
|
G |
Snd1 |
staphylococcal nuclease and tudor domain containing 1 |
decreases expression |
ISO |
Cytarabine results in decreased expression of SND1 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 4:57,095,205...57,494,501
Ensembl chr 4:57,095,208...57,530,843
|
|
G |
Snf8 |
SNF8 subunit of ESCRT-II |
decreases expression |
ISO |
Cytarabine results in decreased expression of SNF8 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr10:80,984,337...80,996,724
Ensembl chr10:80,984,363...80,996,734
|
|
G |
Sorbs2 |
sorbin and SH3 domain containing 2 |
increases expression |
ISO |
Cytarabine results in increased expression of SORBS2 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr16:46,435,220...46,748,743
Ensembl chr16:46,435,237...46,626,514
|
|
G |
Sox21 |
SRY-box transcription factor 21 |
increases expression |
ISO |
Cytarabine results in increased expression of SOX21 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr15:95,292,429...95,296,024
Ensembl chr15:95,292,265...95,296,091
|
|
G |
Sox3 |
SRY-box transcription factor 3 |
increases expression |
ISO |
Cytarabine results in increased expression of SOX3 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr X:139,308,608...139,310,687
Ensembl chr X:139,309,329...139,310,678
|
|
G |
Spag16 |
sperm associated antigen 16 |
increases expression |
ISO |
Cytarabine results in increased expression of SPAG16 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 9:71,333,005...72,252,772
Ensembl chr 9:71,332,992...72,252,708
|
|
G |
Sparc |
secreted protein acidic and cysteine rich |
decreases expression |
ISO |
Cytarabine results in decreased expression of SPARC mRNA |
CTD |
PMID:21198554 |
|
NCBI chr10:39,516,394...39,538,252
Ensembl chr10:39,516,406...39,538,396
|
|
G |
Spata7 |
spermatogenesis associated 7 |
increases expression |
ISO |
Cytarabine results in increased expression of SPATA7 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 6:117,879,828...117,925,284
Ensembl chr 6:117,879,823...117,925,284
|
|
G |
Spin4 |
spindlin family, member 4 |
decreases expression |
ISO |
Cytarabine results in decreased expression of SPIN4 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr X:59,888,728...59,892,817
Ensembl chr X:59,891,581...59,892,330
|
|
G |
Spink1 |
serine peptidase inhibitor, Kazal type 1 |
increases expression |
ISO |
Cytarabine results in increased expression of SPINK1 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr18:35,870,723...35,882,693
Ensembl chr18:35,824,550...35,882,642
|
|
G |
Spon1 |
spondin 1 |
decreases expression |
ISO |
Cytarabine results in decreased expression of SPON1 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 1:167,929,049...168,228,239
Ensembl chr 1:167,928,972...168,228,226
|
|
G |
Sptlc3 |
serine palmitoyltransferase, long chain base subunit 3 |
decreases expression |
ISO |
Cytarabine results in decreased expression of SPTLC3 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 3:126,847,878...126,978,010
Ensembl chr 3:126,847,878...126,978,010
|
|
G |
Srgap3 |
SLIT-ROBO Rho GTPase activating protein 3 |
increases expression |
ISO |
Cytarabine results in increased expression of SRGAP3 mRNA |
CTD |
PMID:21198554 PMID:33770205 |
|
NCBI chr 4:145,839,369...146,070,556
Ensembl chr 4:145,840,078...146,070,575
|
|
G |
Srgn |
serglycin |
increases expression |
ISO |
Cytarabine results in increased expression of SRGN mRNA |
CTD |
PMID:19194470 |
|
NCBI chr20:30,442,810...30,479,549
Ensembl chr20:30,442,813...30,457,406
|
|
G |
Srxn1 |
sulfiredoxin 1 |
increases expression |
ISO |
Cytarabine results in increased expression of SRXN1 mRNA |
CTD |
PMID:22003191 |
|
NCBI chr 3:140,604,490...140,610,050
Ensembl chr 3:140,599,608...140,628,448
|
|
G |
Ssuh2 |
ssu-2 homolog |
increases expression |
ISO |
Cytarabine results in increased expression of SSUH2 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 4:145,502,942...145,521,881
Ensembl chr 4:145,503,185...145,521,735
|
|
G |
St18 |
ST18 C2H2C-type zinc finger transcription factor |
increases expression |
ISO |
Cytarabine results in increased expression of ST18 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 5:12,582,493...12,914,221
Ensembl chr 5:12,584,110...12,671,790
|
|
G |
St3gal1 |
ST3 beta-galactoside alpha-2,3-sialyltransferase 1 |
decreases expression |
ISO |
Cytarabine results in decreased expression of ST3GAL1 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 7:98,845,270...98,913,409
Ensembl chr 7:98,845,270...98,913,236
|
|
G |
St3gal5 |
ST3 beta-galactoside alpha-2,3-sialyltransferase 5 |
decreases expression |
ISO |
Cytarabine results in decreased expression of ST3GAL5 mRNA |
CTD |
PMID:33770205 |
|
NCBI chr 4:104,134,613...104,192,558
Ensembl chr 4:104,134,613...104,192,558
|
|
G |
St3gal6 |
ST3 beta-galactoside alpha-2,3-sialyltransferase 6 |
decreases expression |
ISO |
Cytarabine results in decreased expression of ST3GAL6 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr11:42,061,282...42,121,801
Ensembl chr11:42,077,621...42,121,776
|
|
G |
St6galnac3 |
ST6 N-acetylgalactosaminide alpha-2,6-sialyltransferase 3 |
decreases expression |
ISO |
Cytarabine results in decreased expression of ST6GALNAC3 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 2:242,129,755...242,645,120
Ensembl chr 2:242,129,763...242,645,133
|
|
G |
St6galnac6 |
ST6 N-acetylgalactosaminide alpha-2,6-sialyltransferase 6 |
decreases expression |
ISO |
Cytarabine results in decreased expression of ST6GALNAC6 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 3:15,894,275...15,907,502
Ensembl chr 3:15,885,968...15,907,496
|
|
G |
Stmn4 |
stathmin 4 |
increases response to substance |
ISO |
STMN4 results in increased susceptibility to Cytarabine |
CTD |
PMID:21755009 |
|
NCBI chr15:40,541,305...40,559,253
Ensembl chr15:40,541,357...40,559,253
|
|
G |
Stom |
stomatin |
decreases expression |
ISO |
Cytarabine results in decreased expression of STOM mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 3:18,645,058...18,667,343
Ensembl chr 3:18,644,378...18,667,354
|
|
G |
Ston1 |
stonin 1 |
decreases expression |
ISO |
Cytarabine results in decreased expression of STON1 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 6:5,843,186...5,892,557
Ensembl chr 6:5,843,185...5,892,449
|
|
G |
Surf4 |
surfeit 4 |
decreases expression |
ISO |
Cytarabine results in decreased expression of SURF4 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 3:10,248,360...10,261,537
Ensembl chr 3:10,241,837...10,263,315
|
|
G |
Svep1 |
sushi, von Willebrand factor type A, EGF and pentraxin domain containing 1 |
decreases expression |
ISO |
Cytarabine results in decreased expression of SVEP1 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 5:72,811,200...72,988,185
Ensembl chr 5:72,811,410...72,988,525
|
|
G |
Sytl2 |
synaptotagmin-like 2 |
increases expression |
ISO |
Cytarabine results in increased expression of SYTL2 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 1:144,272,870...144,379,310
Ensembl chr 1:144,273,360...144,379,222
|
|
G |
Tac1 |
tachykinin, precursor 1 |
increases expression |
ISO |
Cytarabine results in increased expression of TAC1 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 4:35,679,183...35,687,180
Ensembl chr 4:35,679,704...35,687,178
|
|
G |
Tac3 |
tachykinin precursor 3 |
decreases expression |
ISO |
Cytarabine results in decreased expression of TAC3 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 7:63,562,552...63,569,170
Ensembl chr 7:63,562,552...63,569,170
|
|
G |
Tagln |
transgelin |
increases expression |
ISO |
Cytarabine results in increased expression of TAGLN mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 8:46,224,939...46,230,413
Ensembl chr 8:46,222,472...46,230,668
|
|
G |
Tbc1d4 |
TBC1 domain family, member 4 |
decreases expression |
ISO |
Cytarabine results in decreased expression of TBC1D4 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr15:78,256,030...78,434,168
Ensembl chr15:78,257,121...78,434,265
|
|
G |
Tceal7 |
transcription elongation factor A like 7 |
increases expression |
ISO |
Cytarabine results in increased expression of TCEAL7 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr X:99,228,405...99,230,551
Ensembl chr X:99,228,458...99,230,543
|
|
G |
Tcf12 |
transcription factor 12 |
increases expression |
ISO |
Cytarabine results in increased expression of TCF12 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 8:72,490,447...72,799,265
Ensembl chr 8:72,492,567...72,799,201
|
|
G |
Tcf21 |
transcription factor 21 |
decreases expression |
ISO |
Cytarabine results in decreased expression of TCF21 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 1:22,701,353...22,704,212
Ensembl chr 1:22,701,353...22,704,202
|
|
G |
Tcf25 |
transcription factor 25 |
decreases expression |
ISO |
Cytarabine results in decreased expression of TCF25 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr19:51,415,341...51,449,725
Ensembl chr19:51,415,543...51,449,723
|
|
G |
Tecrl |
trans-2,3-enoyl-CoA reductase-like |
decreases expression |
ISO |
Cytarabine results in decreased expression of TECRL mRNA |
CTD |
PMID:21198554 |
|
NCBI chr14:24,732,241...24,805,272
Ensembl chr14:24,732,241...24,805,272
|
|
G |
Tek |
TEK receptor tyrosine kinase |
decreases expression |
ISO |
Cytarabine results in decreased expression of TEK mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 5:109,607,077...109,733,805
Ensembl chr 5:109,607,077...109,733,804
|
|
G |
Tent5a |
terminal nucleotidyltransferase 5A |
decreases expression |
ISO |
Cytarabine results in decreased expression of TENT5A mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 8:86,222,294...86,229,045
Ensembl chr 8:86,225,357...86,229,045
|
|
G |
Tent5c |
terminal nucleotidyltransferase 5C |
decreases expression |
ISO |
Cytarabine results in decreased expression of TENT5C mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 2:187,853,026...187,875,260
Ensembl chr 2:187,853,024...187,894,744
|
|
G |
Tfap2a |
transcription factor AP-2 alpha |
multiple interactions increases expression |
ISO |
2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [Cytarabine results in increased expression of TFAP2A mRNA] |
CTD |
PMID:23264188 |
|
NCBI chr17:24,028,716...24,047,507
Ensembl chr17:24,024,432...24,047,507
|
|
G |
Tfe3 |
transcription factor binding to IGHM enhancer 3 |
increases expression |
ISO |
Cytarabine results in increased expression of TFE3 mRNA |
CTD |
PMID:19194470 |
|
NCBI chr X:14,729,547...14,742,830
Ensembl chr X:14,729,550...14,742,571
|
|
G |
Tff3 |
trefoil factor 3 |
increases expression |
ISO |
Cytarabine results in increased expression of TFF3 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr20:9,193,259...9,197,969
Ensembl chr20:9,193,262...9,198,054
|
|
G |
Tfpi |
tissue factor pathway inhibitor |
decreases expression |
ISO |
Cytarabine results in decreased expression of TFPI mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 3:69,533,156...69,582,547
Ensembl chr 3:69,533,156...69,576,880
|
|
G |
Tgfbr3 |
transforming growth factor beta receptor 3 |
decreases expression |
ISO |
Cytarabine results in decreased expression of TGFBR3 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr14:2,489,397...2,665,383
Ensembl chr14:2,489,397...2,663,341
|
|
G |
Th |
tyrosine hydroxylase |
decreases expression |
ISO |
Cytarabine results in decreased expression of TH protein |
CTD |
PMID:21198554 |
|
NCBI chr 1:198,071,500...198,078,832
Ensembl chr 1:198,071,503...198,109,767
|
|
G |
Thbs1 |
thrombospondin 1 |
increases expression |
ISO |
Cytarabine results in increased expression of THBS1 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 3:105,056,293...105,071,445
Ensembl chr 3:105,056,292...105,071,440
|
|
G |
Thy1 |
Thy-1 cell surface antigen |
decreases expression |
ISO |
Cytarabine results in decreased expression of THY1 mRNA |
CTD |
PMID:19194470 |
|
NCBI chr 8:44,389,495...44,394,688
Ensembl chr 8:44,389,513...44,394,659
|
|
G |
Timp1 |
TIMP metallopeptidase inhibitor 1 |
decreases expression |
ISO |
Cytarabine results in decreased expression of TIMP1 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr X:1,212,969...1,217,714
Ensembl chr X:1,212,972...1,217,664
|
|
G |
Timp3 |
TIMP metallopeptidase inhibitor 3 |
affects response to substance decreases response to substance |
ISO |
TIMP3 protein affects the susceptibility to Cytarabine TIMP3 gene modified form results in decreased susceptibility to Cytarabine |
CTD |
PMID:18202788 |
|
NCBI chr 7:17,520,827...17,571,850
Ensembl chr 7:17,521,919...17,571,839
|
|
G |
Tk1 |
thymidine kinase 1 |
decreases activity decreases expression |
ISO |
Cytarabine results in decreased activity of TK1 protein Cytarabine results in decreased expression of TK1 mRNA |
CTD |
PMID:12893260 |
|
NCBI chr10:103,034,755...103,046,125
Ensembl chr10:103,031,521...103,046,920
|
|
G |
Tk2 |
thymidine kinase 2 |
decreases expression decreases activity |
ISO |
Cytarabine results in decreased expression of TK2 mRNA Cytarabine results in decreased activity of TK2 protein |
CTD |
PMID:12893260 |
|
NCBI chr19:708,859...731,786
Ensembl chr19:708,891...730,924
|
|
G |
Tln2 |
talin 2 |
decreases expression |
ISO |
Cytarabine results in decreased expression of TLN2 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 8:67,830,920...68,252,240
Ensembl chr 8:67,834,326...68,252,219
|
|
G |
Tmed1 |
transmembrane p24 trafficking protein 1 |
decreases expression |
ISO |
Cytarabine results in decreased expression of TMED1 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 8:20,059,937...20,063,567
Ensembl chr 8:20,059,892...20,063,677
|
|
G |
Tmed9 |
transmembrane p24 trafficking protein 9 |
decreases expression |
ISO |
Cytarabine results in decreased expression of TMED9 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr17:9,029,646...9,034,160
Ensembl chr17:9,029,646...9,034,176
|
|
G |
Tmem200a |
transmembrane protein 200A |
decreases expression |
ISO |
Cytarabine results in decreased expression of TMEM200A mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 1:19,323,646...19,408,324
Ensembl chr 1:19,323,829...19,406,453
|
|
G |
Tmem45a |
transmembrane protein 45A |
decreases expression |
ISO |
Cytarabine results in decreased expression of TMEM45A mRNA |
CTD |
PMID:21198554 |
|
NCBI chr11:43,713,309...43,799,526
Ensembl chr11:43,713,782...43,799,526
|
|
G |
Tmem62 |
transmembrane protein 62 |
increases expression |
ISO |
Cytarabine results in increased expression of TMEM62 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 3:107,921,940...107,961,830
Ensembl chr 3:107,927,307...107,961,795
|
|
G |
Tmem88 |
transmembrane protein 88 |
decreases expression |
ISO |
Cytarabine results in decreased expression of TMEM88 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr10:54,118,752...54,120,447
Ensembl chr10:54,118,752...54,120,447
|
|
G |
Tmem98 |
transmembrane protein 98 |
decreases expression |
ISO |
Cytarabine results in decreased expression of TMEM98 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr10:65,796,173...65,807,082
Ensembl chr10:65,796,145...65,807,079
|
|
G |
Tnf |
tumor necrosis factor |
increases expression |
ISO |
Cytarabine results in increased expression of TNF protein |
CTD |
PMID:8318674 PMID:11745875 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tnfaip3 |
TNF alpha induced protein 3 |
decreases expression |
ISO |
Cytarabine results in decreased expression of TNFAIP3 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 1:13,709,211...13,724,291
Ensembl chr 1:13,709,206...13,725,282
|
|
G |
Tnfrsf19 |
TNF receptor superfamily member 19 |
decreases expression |
ISO |
Cytarabine results in decreased expression of TNFRSF19 mRNA |
CTD |
PMID:33770205 |
|
NCBI chr15:35,092,206...35,158,472
Ensembl chr15:35,092,206...35,180,795
|
|
G |
Tnfsf10 |
TNF superfamily member 10 |
multiple interactions increases expression |
ISO |
[Cytarabine co-treated with TNFSF10 protein] results in increased activity of CASP3 protein; [Cytarabine co-treated with TNFSF10 protein] results in increased activity of CASP8 protein; [Cytarabine co-treated with TNFSF10 protein] results in increased cleavage of PARP1 protein; [Cytarabine co-treated with TNFSF10 protein] results in increased expression of BID protein; Cytarabine promotes the reaction [TNFSF10 protein results in increased activity of CASP8 protein]; Cytarabine promotes the reaction [TNFSF10 protein results in increased expression of TNFRSF10B protein] Cytarabine results in increased expression of TNFSF10 mRNA |
CTD |
PMID:12780785 PMID:18549619 PMID:19194470 |
|
NCBI chr 2:110,199,835...110,227,239
Ensembl chr 2:110,207,916...110,225,135
|
|
G |
Tnnt2 |
troponin T2, cardiac type |
decreases expression |
ISO |
Cytarabine results in decreased expression of TNNT2 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr13:47,267,325...47,285,390
Ensembl chr13:47,267,204...47,285,388
|
|
G |
Tnrc6a |
trinucleotide repeat containing adaptor 6A |
increases expression |
ISO |
Cytarabine results in increased expression of TNRC6A mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 1:177,561,898...177,715,669
Ensembl chr 1:177,646,030...177,715,660
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions affects activity increases activity affects response to substance increases response to substance increases expression increases phosphorylation |
ISO EXP |
[fludarabine co-treated with Cytarabine co-treated with docetaxel] results in increased expression of TP53 protein; Caffeine inhibits the reaction [Cytarabine results in increased expression of TP53 protein]; Caffeine inhibits the reaction [Cytarabine results in increased phosphorylation of TP53 protein] Cytarabine affects the activity of TP53 protein; Cytarabine metabolite affects the activity of TP53 protein Cytarabine results in increased activity of TP53 protein TRP53 protein affects the susceptibility to Cytarabine TP53 gene mutant form results in increased susceptibility to Cytarabine [Cytarabine results in increased expression of TP53 protein] which results in increased expression of BAX protein; Cytarabine results in increased expression of TP53 protein |
CTD |
PMID:9703875 PMID:9880587 PMID:10200513 PMID:12082016 PMID:12781215 PMID:14766721 PMID:15203180 PMID:17977830 PMID:19628630 PMID:20477944 PMID:22010212 PMID:22212197 PMID:24675086 PMID:35435491 More...
|
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Tp53i11 |
tumor protein p53 inducible protein 11 |
increases response to substance |
ISO |
TP53I11 results in increased susceptibility to Cytarabine |
CTD |
PMID:21755009 |
|
NCBI chr 3:79,144,824...79,160,056
Ensembl chr 3:79,144,895...79,160,050
|
|
G |
Tpk1 |
thiamin pyrophosphokinase 1 |
decreases expression |
ISO |
Cytarabine results in decreased expression of TPK1 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 4:72,170,134...72,557,707
Ensembl chr 4:72,170,134...72,557,694
|
|
G |
Tpst1 |
tyrosylprotein sulfotransferase 1 |
decreases expression |
ISO |
Cytarabine results in decreased expression of TPST1 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr12:26,544,536...26,605,706
Ensembl chr12:26,544,536...26,605,704
|
|
G |
Trim5 |
tripartite motif-containing 5 |
decreases expression |
ISO |
Cytarabine results in decreased expression of TRIM5 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 1:158,720,407...158,737,393
Ensembl chr 1:158,720,410...158,814,012
|
|
G |
Trim6 |
tripartite motif containing 6 |
decreases expression |
ISO |
Cytarabine results in decreased expression of TRIM6 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 1:158,683,746...158,696,936
Ensembl chr 1:158,683,746...158,696,914
|
|
G |
Trpv1 |
transient receptor potential cation channel, subfamily V, member 1 |
affects localization |
ISO |
Cytarabine affects the localization of TRPV1 protein |
CTD |
PMID:18414789 |
|
NCBI chr10:57,851,428...57,876,513
Ensembl chr10:57,851,428...57,876,513
|
|
G |
Trpv2 |
transient receptor potential cation channel, subfamily V, member 2 |
decreases expression |
ISO |
Cytarabine results in decreased expression of TRPV2 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr10:47,265,524...47,294,263
Ensembl chr10:47,272,931...47,294,260
|
|
G |
Tspan4 |
tetraspanin 4 |
decreases expression |
ISO |
Cytarabine results in decreased expression of TSPAN4 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 1:196,571,307...196,593,842
Ensembl chr 1:196,572,228...196,617,448
|
|
G |
Tspo |
translocator protein |
decreases expression |
ISO |
Cytarabine results in decreased expression of TSPO mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 7:114,720,188...114,730,450
Ensembl chr 7:114,720,188...114,730,450
|
|
G |
Tst |
thiosulfate sulfurtransferase |
decreases expression |
ISO |
Cytarabine results in decreased expression of TST mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 7:109,948,061...109,955,378
Ensembl chr 7:109,948,062...109,957,216
|
|
G |
Ttyh1 |
tweety family member 1 |
increases expression |
ISO |
Cytarabine results in increased expression of TTYH1 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 1:70,053,312...70,071,872
Ensembl chr 1:70,053,324...70,071,845
|
|
G |
Tubb3 |
tubulin, beta 3 class III |
decreases expression |
ISO |
Cytarabine results in decreased expression of TUBB3 protein |
CTD |
PMID:21198554 |
|
NCBI chr19:51,457,187...51,466,243
Ensembl chr19:51,457,184...51,466,243
|
|
G |
Tyms |
thymidylate synthetase |
affects response to substance increases activity |
ISO |
TYMS gene polymorphism affects the susceptibility to Cytarabine Cytarabine results in increased activity of TYMS protein |
CTD |
PMID:15713801 PMID:15816533 |
|
NCBI chr 9:113,313,454...113,329,551
Ensembl chr 9:113,313,452...113,329,536
|
|
G |
U2af1 |
U2 small nuclear RNA auxiliary factor 1 |
decreases expression |
ISO |
Cytarabine results in decreased expression of U2AF1 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr20:9,742,904...9,753,840
Ensembl chr20:9,742,905...9,753,832
|
|
G |
Ube2c |
ubiquitin-conjugating enzyme E2C |
decreases expression |
ISO |
Cytarabine results in decreased expression of UBE2C mRNA |
CTD |
PMID:17374387 |
|
NCBI chr 3:153,506,636...153,509,036
Ensembl chr 3:153,506,636...153,513,339
|
|
G |
Ubl3 |
ubiquitin-like 3 |
increases expression |
ISO |
Cytarabine results in increased expression of UBL3 mRNA |
CTD |
PMID:19194470 |
|
NCBI chr12:6,473,684...6,518,331
Ensembl chr12:6,473,460...6,518,862
|
|
G |
Usp7 |
ubiquitin specific peptidase 7 |
decreases expression |
ISO |
Cytarabine results in decreased expression of USP7 mRNA |
CTD |
PMID:19194470 |
|
NCBI chr10:6,880,684...6,925,355
Ensembl chr10:6,828,795...6,925,355
|
|
G |
Vasn |
vasorin |
decreases expression |
ISO |
Cytarabine results in decreased expression of VASN mRNA |
CTD |
PMID:21198554 |
|
NCBI chr10:10,917,750...10,928,259
Ensembl chr10:10,917,605...10,928,357
|
|
G |
Vcam1 |
vascular cell adhesion molecule 1 |
increases expression |
ISO |
Cytarabine results in increased expression of VCAM1 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 2:204,038,120...204,057,852
Ensembl chr 2:204,038,114...204,057,958
|
|
G |
Vdr |
vitamin D receptor |
affects response to substance |
ISO |
VDR gene polymorphism affects the susceptibility to Cytarabine |
CTD |
PMID:15713801 |
|
NCBI chr 7:128,987,981...129,037,677
Ensembl chr 7:128,987,981...129,037,677
|
|
G |
Vegfc |
vascular endothelial growth factor C |
multiple interactions decreases response to substance |
ISO |
EDN1 mutant form inhibits the reaction [VEGFC protein results in decreased susceptibility to Cytarabine]; PTGS2 mutant form inhibits the reaction [VEGFC protein results in decreased susceptibility to Cytarabine] EDN1 mutant form affects the reaction [VEGFC protein results in decreased susceptibility to Cytarabine]; PTGS2 mutant form affects the reaction [VEGFC protein results in decreased susceptibility to Cytarabine] |
CTD |
PMID:24184161 |
|
NCBI chr16:37,712,251...37,827,845
Ensembl chr16:37,712,262...37,827,848
|
|
G |
Vezf1 |
vascular endothelial zinc finger 1 |
increases expression |
ISO |
Cytarabine results in increased expression of VEZF1 mRNA |
CTD |
PMID:19194470 |
|
NCBI chr10:72,859,669...72,876,111
Ensembl chr10:72,859,877...72,876,111
|
|
G |
Vgll4 |
vestigial-like family member 4 |
decreases expression |
ISO |
Cytarabine results in decreased expression of VGLL4 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 4:147,925,630...148,038,519
Ensembl chr 4:147,927,034...148,038,471
|
|
G |
Vrk2 |
VRK serine/threonine kinase 2 |
decreases expression |
ISO |
Cytarabine results in decreased expression of VRK2 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr14:100,313,771...100,434,520
Ensembl chr14:100,313,601...100,434,527
|
|
G |
Wfdc3 |
WAP four-disulfide core domain 3 |
decreases expression |
ISO |
Cytarabine results in decreased expression of WFDC3 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 3:153,464,862...153,478,952
Ensembl chr 3:153,464,862...153,478,952
|
|
G |
Wipf1 |
WAS/WASL interacting protein family, member 1 |
decreases expression |
ISO |
Cytarabine results in decreased expression of WIPF1 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 3:58,314,521...58,416,668
Ensembl chr 3:58,314,542...58,372,742
|
|
G |
Xiap |
X-linked inhibitor of apoptosis |
increases response to substance |
ISO |
XIAP protein results in increased susceptibility to Cytarabine |
CTD |
PMID:10815900 |
|
NCBI chr X:120,890,537...120,938,413
Ensembl chr X:120,897,907...120,934,700
|
|
G |
Xrcc1 |
X-ray repair cross complementing 1 |
increases expression |
ISO |
Cytarabine results in increased expression of XRCC1 mRNA |
CTD |
PMID:19194470 |
|
NCBI chr 1:80,140,495...80,168,705
Ensembl chr 1:80,141,207...80,168,701
|
|
G |
Yif1a |
Yip1 interacting factor homolog A, membrane trafficking protein |
decreases expression |
ISO |
Cytarabine results in decreased expression of YIF1A mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 1:202,394,923...202,399,125
Ensembl chr 1:202,394,897...202,399,427
|
|
G |
Zc3hav1 |
zinc finger CCCH-type containing, antiviral 1 |
decreases expression |
ISO |
Cytarabine results in decreased expression of ZC3HAV1 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 4:67,012,129...67,062,428
Ensembl chr 4:67,012,185...67,062,428
|
|
G |
Zfhx4 |
zinc finger homeobox 4 |
increases expression |
ISO |
Cytarabine results in increased expression of ZFHX4 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 2:96,224,763...96,408,245
Ensembl chr 2:96,224,767...96,408,228
|
|
G |
Zfp282 |
zinc finger protein 282 |
increases expression |
ISO |
Cytarabine results in increased expression of ZNF282 mRNA |
CTD |
PMID:33770205 |
|
NCBI chr 4:76,884,996...76,910,250
Ensembl chr 4:76,884,924...76,911,370
|
|
G |
Zfp423 |
zinc finger protein 423 |
increases expression |
ISO |
Cytarabine results in increased expression of ZNF423 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr19:19,111,213...19,407,373
Ensembl chr19:19,110,238...19,407,373
|
|
G |
Zfp467 |
zinc finger protein 467 |
decreases expression |
ISO |
Cytarabine results in decreased expression of ZNF467 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 4:77,385,752...77,394,709
Ensembl chr 4:77,385,758...77,392,229
|
|
G |
Zfpm2 |
zinc finger protein, multitype 2 |
decreases expression |
ISO |
Cytarabine results in decreased expression of ZFPM2 mRNA |
CTD |
PMID:21198554 |
|
NCBI chr 7:71,678,658...72,116,209
Ensembl chr 7:71,678,880...72,116,205
|
|
|
G |
Adora1 |
adenosine A1 receptor |
increases activity |
EXP |
Cytidine results in increased activity of ADORA1 protein |
CTD |
PMID:18313046 |
|
NCBI chr13:45,658,872...45,695,821
Ensembl chr13:45,658,872...45,695,801
|
|
G |
Adora2a |
adenosine A2a receptor |
increases activity |
EXP |
Cytidine results in increased activity of ADORA2A protein |
CTD |
PMID:18313046 |
|
NCBI chr20:13,315,848...13,333,386
Ensembl chr20:13,315,853...13,333,386
|
|
|